An Introduction to Ion Channels
===============================

**Overview**: Ion channels are pore-forming proteins that allow the flow of ions across membranes, either plasma membranes or the membranes of intracellular organelles (Hille, 2001). Many ion channels (such as most Na, K Ca and some Cl channels) are gated by voltage but others (such as certain K and Cl channels, TRP channels, ryanodine receptors and IP~3~ receptors) are relatively voltage-insensitive and are gated by second messengers and other intracellular and/or extracellular mediators. As such, there is some blurring of the boundaries between "ion channels" and "ligand-gated channels" which are compiled separately in the Concise Guide to PHARMACOLOGY 2013/14.

Resolution of ion channel structures, beginning with K channels (Doyle *et al.,* 1998) then Cl channels (Dutzler *et al.,* 2002) and most recently Na channels (Payandeh *et al.,* 2011) has greatly improved understanding of the structural basis behind ion channel function. Many ion channels (e.g., K, Na, Ca, HCN and TRP channels) share several structural similarities. These channels are thought to have evolved from a common ancestor and have been classified together as the "voltage-gated-like (VGL) ion channel chanome" (see Yu *et al.,* 2005). Other ion channels, however, such as Cl channels, aquaporins and connexins, have completely different structural properties to the VGL channels, having evolved quite separately.

Currently, ion channels (including ligand-gated ion channels) represent the second largest target for existing drugs after G protein-coupled receptors (Overington *et al.,* 2006). However, the advent of novel, faster screening techniques for compounds acting on ion channels (Dunlop *et al.,* 2008) suggests that these proteins represent promising targets for the development of additional, novel therapeutic agents in the near future.
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Acid-sensing (proton-gated) ion channels (ASICs)
================================================

Overview
--------

Acid-sensing ion channels (ASICs, provisional nomenclature; [@b27],[@b47]) are members of a Na^+^ channel superfamily that includes the epithelial Na^+^ channel (ENaC), the FMRF-amide activated channel (FaNaC) of invertebrates, the degenerins (DEG) of *Caenorhabitis elegans*, channels in *Drosophila melanogaster* and 'orphan' channels that include BLINaC [@b34] and INaC [@b35]. ASIC subunits contain two TM domains and assemble as homo- or hetero-trimers [@b22],[@b26] to form proton-gated, voltage-insensitive, Na^+^ permeable, channels (reviewed in [@b23]). Splice variants of ASIC1 \[provisionally termed ASIC1a (ASIC, ASICα, BNaC2α) [@b43], ASIC1b (ASICβ, BNaC2β) [@b8] and ASIC1b2 (ASICβ2) [@b39]; note that ASIC1a is also permeable to Ca^2+^\] and ASIC2 \[provisionally termed ASIC2a (MDEG1, BNaC1α, BNC1α) [@b21],[@b33],[@b44] and ASIC2b (MDEG2, BNaC1β) [@b28] \] have been cloned. Unlike ASIC2a (listed in table), heterologous expression of ASIC2b alone does not support H^+^-gated currents. A third member, ASIC3 (DRASIC, TNaC1) [@b42], has been identified. A fourth mammalian member of the family (ASIC4/SPASIC) does not support a proton-gated channel in heterologous expression systems and is reported to down regulate the expression of ASIC1a and ASIC3 [@b1],[@b16],[@b24]. ASIC channels are primarily expressed in central and peripheral neurons including nociceptors where they participate in neuronal sensitivity to acidosis. They have also been detected in taste receptor cells (ASIC1-3), photoreceptors and retinal cells (ASIC1-3), cochlear hair cells (ASIC1b), testis (hASIC3), pituitary gland (ASIC4), lung epithelial cells (ASIC1a and -3), urothelial cells, adipose cells (ASIC3), vascular smooth muscle cells (ASIC1-3), immune cells (ASIC1,-3 and -4) and bone (ASIC1-3). The activation of ASIC1a within the central nervous system contributes to neuronal injury caused by focal ischemia [@b48] and to axonal degeneration in autoimmune inflammation in a mouse model of multiple sclerosis [@b20]. However, activation of ASIC1a can terminate seizures [@b51]. Peripheral ASIC3-containing channels play a role in post-operative pain [@b12]. Further proposed roles for centrally and peripherally located ASICs are reviewed in [@b47] and [@b27]. The relationship of the cloned ASICs to endogenously expressed proton-gated ion channels is becoming established [@b14],[@b15],[@b19],[@b25],[@b27],[@b29],[@b38],[@b45]--[@b47]. Heterologously expressed heteromultimers form ion channels with altered kinetics, ion selectivity, pH- sensitivity and sensitivity to blockers that resemble some of the native proton activated currents recorded from neurones [@b3],[@b6],[@b19],[@b28].

Subunits
========

  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     ASIC1                                                                                                                                                                                                                                                                                                                                                                                                                                                     ASIC2                                                                                                                      ASIC3
  HGNC, UniProt                    ASIC1, P78348                                                                                                                                                                                                                                                                                                                                                                                                                                             ASIC2, Q16515                                                                                                              ASIC3, Q9UHC3
  Endogenous activators (EC~50~)   Extracellular H+ (ASIC1a) (∼1.6x10^-7^ -- 6.3x10^-7^ M), Extracellular H+ (ASIC1b) (∼6.3x10^-7^ -- 8x10^-6^ M)                                                                                                                                                                                                                                                                                                                                            Extracellular H+ (∼1x10^-5^ -- 8x10^-5^ M)                                                                                 Extracellular H+ (transient component) (∼2x10^-7^ -- 6.3x10^-7^ M), Extracellular H+ (sustained component) (∼5x10^-5^ -- 3.5x10^-4^ M)
  Activators (EC~50~)              --                                                                                                                                                                                                                                                                                                                                                                                                                                                        --                                                                                                                         GMQ (largely non-desensitizing; at pH 7.4) (∼1x10^-3^ M), arcaine (at pH 7.4) (∼1.2x10^-3^ M), agmatine (at pH 7.4) (∼9.8x10^-3^ M)
  Channel Blockers (IC~50~)        psalmotoxin 1 (ASIC1a) (9x10^-10^ M), Zn2+ (ASIC1a) (∼7x10^-9^ M), Pb2+ (ASIC1b) (∼1.5x10^-6^ M), A317567 (ASIC1a) (∼2x10^-6^ M), Pb2+ (ASIC1a) (∼4x10^-6^ M), amiloride (ASIC1a) (1x10^-5^ M), benzamil (ASIC1a) (1x10^-5^ M), EIPA (ASIC1a) (1x10^-5^ M), nafamostat (ASIC1a) (∼1.3x10^-5^ M), amiloride (ASIC1b) (2.1x10^-5^ -- 2.3x10^-5^ M), flurbiprofen (ASIC1a) (3.5x10^-4^ M), ibuprofen (ASIC1a) (∼3.5x10^-4^ M), Ni2+ (ASIC1a) (∼6x10^-4^ M)   amiloride (2.8x10^-5^ M), A317567 (∼3x10^-5^ M), nafamostat (∼7x10^-5^ M), Cd2+ (∼1x10^-3^ M)                              APETx2 (transient component only) (6.3x10^-8^ M), nafamostat (transient component) (∼2.5x10^-6^ M), A317567 (∼1x10^-5^ M), amiloride (transient component only - sustained component enhanced by 200μM amiloride at pH 4) (1.6x10^-5^ -- 6.3x10^-5^ M), Gd3+ (4x10^-5^ M), Zn2+ (6.1x10^-5^ M), aspirin (sustained component) (9.2x10^-5^ M), diclofenac (sustained component) (9.2x10^-5^ M), salicylic acid (sustained component) (2.6x10^-4^ M)
  Radioligands (*K*~d~)            \[125I\]psalmotoxin 1 (ASIC1a) (2.13x10^-10^ M)                                                                                                                                                                                                                                                                                                                                                                                                           --                                                                                                                         --
  Functional characteristics       **ASIC1a:** γ ∼14pS, P~Na~/P~K~ = 5--13, P~Na~/P~Ca~ =2.5, rapid activation rate (5.8--13.7 ms), rapid inactivation rate (1.2--4 s) @ pH 6.0, slow recovery (5.3--13s) @ pH 7.4 **ASIC1b:** γ ∼ 19 pS, P~Na~/P~K~ =14.0, P~Na~ ≫ P~Ca~, rapid activation rate (9.9 ms), rapid inactivation rate (0.9--1.7 s) @ pH 6.0, slow recovery (4.4--7.7 s) @ pH 7.4                                                                                                γ∼10.4--13.4 pS, P~Na~/P~K~ =10, P~Na~/P~Ca~ = 20, rapid activation rate, moderate inactivation rate (3.3--5.5 s) @ pH 5   γ∼ 13--15 pS; biphasic response consisting of rapidly inactivating transient and sustained components; very rapid activation (\<5 ms) and inactivation (0.4s); fast recovery (0.4--0.6 s) @ pH 7.4, transient component partially inactivated at pH 7.2
  Comment                          ASIC1a and ASIC1b are also blocked by diarylamidines (IC~50~ ∼3 μM for ASIC1a)                                                                                                                                                                                                                                                                                                                                                                            ASIC2 is also blocked by diarylamidines                                                                                    ASIC3 is also blocked by diarylamidines
  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

psalmotoxin 1 (PcTx1) inhibits ASIC1a by modifying activation and desensitization by H^+^, but promotes ASIC1b opening. PcTx1 has little effect upon ASIC2a, ASIC3, or ASIC1a expressed as a heteromultimer with either ASIC2a, or ASIC3 [@b15],[@b19] but does block ASIC1a expressed as a heteromultimer with ASIC2b [@b36]. spermine, which apparently competes with PcTx1 for binding to ASIC1a, selectively enhances the function of the channel [@b17]. Blockade of ASIC1a by PcTx1 activates the endogenous enkephalin pathway and has very potent analgesic effects in rodents [@b31]. APETx2 most potently blocks homomeric ASIC3 channels, but also ASIC2b+ASIC3, ASIC1b+ASIC3, and ASIC1a+ASIC3 heteromeric channels with IC~50~ values of 117 nM, 900 nM and 2 μM, respectively. APETx2 has no effect on ASIC1a, ASIC1b, ASIC2a, or ASIC2a+ASIC3 [@b14],[@b15]. IC~50~ values for A317567 are inferred from blockade of ASIC channels native to dorsal root ganglion neurones [@b18]. The pEC~50~ values for proton activation of ASIC channels are influenced by numerous factors including extracellular di- and poly-valent ions, Zn^2+^, protein kinase C and serine proteases (reviewed in [@b29]). Rapid acidification is required for activation of ASIC1 and ASIC3 due to fast inactivation/desensitization. pEC~50~ values for H^+^-activation of either transient, or sustained, currents mediated by ASIC3 vary in the literature and may reflect species and/or methodological differences [@b4],[@b11],[@b42]. The transient and sustained current components mediated by rASIC3 are selective for Na^+^ [@b42]; for hASIC3 the transient component is Na^+^ selective (PNa/PK \> 10) whereas the sustained current appears non-selective (PNa/PK = 1.6) [@b4],[@b11]. The reducing agents dithiothreitol (DTT) and glutathione (GSH) increase ASIC1a currents expressed in CHO cells and ASIC-like currents in sensory ganglia and central neurons [@b2],[@b9] whereas oxidation, through the formation of intersubunit disulphide bonds, reduces currents mediated by ASIC1a [@b50]. ASIC1a is also irreversibly modulated by extracellular serine proteases, such as trypsin, through proteolytic cleavage [@b41]. Non-steroidal anti-inflammatory drugs (NSAIDs) are direct blockers of ASIC currents at therapeutic concentrations (reviewed in [@b40]). Extracellular Zn^2+^ potentiates proton activation of homomeric and heteromeric channels incorporating ASIC2a, but not homomeric ASIC1a or ASIC3 channels [@b5]. However, removal of contaminating Zn^2+^ by chealation reveals a high affinity block of homomeric ASIC1a and heteromeric ASIC1a+ASIC2 channels by Zn^2+^ indicating complex biphasic actions of the divalent [@b10]. NO potentiates submaximal currents activated by H^+^ mediated by ASIC1a, ASIC1b, ASIC2a and ASIC3 [@b7]. Ammonium activates ASIC channels (most likely ASIC1a) in midbrain dopaminergic neurones: that may be relevant to neuronal disorders associated with hyperammonemia [@b32]. The positive modulation of homomeric, heteromeric and native ASIC channels by the peptide FMRFamide and related substances, such as neuropeptides FF and SF, is reviewed in detail in [@b29]. Inflammatory conditions and particular pro-inflammatory mediators induce overexpression of ASIC-encoding genes, enhance ASIC currents [@b30], and in the case of arachidonic acid directly activate the channel [@b13],[@b37]. The sustained current component mediated by ASIC3 is potentiated by hypertonic solutions in a manner that is synergistic with the effect of arachidonic acid [@b13]. Selective activation of ASIC3 by GMQ at a site separate from the proton binding site is potentiated by mild acidosis and reduced extracellular Ca^2+^ [@b49].

Aquaporins
==========

Overview
--------

Aquaporins and aquaglyceroporins (provisional nomenclature) are membrane channels that allow the permeation of water and certain other small solutes across the cell membrane. Since the isolation and cloning of the first aquaporin (AQP1) [@b54], 12 additional members of the family have been identified, although little is known about the functional properties of two of these (AQP11; Q8NBQ7 and AQP12A; Q8IXF9). The other 11 aquaporins can be divided into two families (aquaporins and aquaglyceroporins) depending on whether they are permeable to glycerol [@b53]. One or more members of this family of proteins have been found to be expressed in almost all tissues of the body. Individual AQP subunits have six transmembrane domains with an inverted symmetry between the first three and last three domains [@b52]. Functional AQPs exist as tetramers but, unusually, each subunit contains a separate pore, so each channel has four pores.

Subunits
========

  ----------------------- ------------- ------------------------------- -------------- ----------------------------------- ------------------------------------- -------------- ------------------------------------------------------------------------------ ------------------------ -------------- ----------------------- -----------------------
  Nomenclature            AQP0          AQP1                            AQP2           AQP3                                AQP4                                  AQP5           AQP6                                                                           AQP7                     AQP8           AQP9                    AQP10
  HGNC, UniProt           MIP, P30301   AQP1, P29972                    AQP2, P41181   AQP3, Q92482                        AQP4, P55087                          AQP5, P55064   AQP6, Q13520                                                                   AQP7, O14520             AQP8, O94778   AQP9, O43315            AQP10, Q96PS8
  Permeability            water (low)   water (high)                    water (high)   water (high), glycerol              water (high)                          water (high)   water (low), anions                                                            water (high), glycerol   water (high)   water (low), glycerol   water (low), glycerol
  Endogenous activators   --            cGMP                            --             --                                  --                                    --             --                                                                             --                       --             --                      --
  Inhibitors              Hg2+          Ag+, Hg2+, tetraethylammonium   Hg2+           Hg2+ (also inhibited by acid pH)    --                                    Hg2+           Hg2+                                                                           Hg2+                     Hg2+           Hg2+, phloretin         Hg2+
  Comment                 --            --                              --             AQP3 is also inhibited by acid pH   AQP4 is inhibited by PKC activation   --             AQP6 is an intracellular channel permeable to anions as well as water [@b55]   --                       --             --                      --
  ----------------------- ------------- ------------------------------- -------------- ----------------------------------- ------------------------------------- -------------- ------------------------------------------------------------------------------ ------------------------ -------------- ----------------------- -----------------------

CatSper and Two-Pore channels
=============================

Overview
--------

CatSper channels (CatSper1--4; nomenclature as agreed by NC-IUPHAR, [@b59]) are putative 6TM, voltage-gated, calcium permeant channels that are presumed to assemble as a tetramer of α-like subunits and mediate the current I~CatSper~. In mammals, CatSper subunits are structurally most closely related to individual domains of voltage-activated calcium channels (Ca~v~) [@b71]. CatSper1 [@b71], CatSper2 [@b70] and CatSpers 3 and 4 [@b61],[@b66],[@b69], in common with a recently identified putative 2TM auxiliary CatSperβ protein [@b65] and two putative 1TM associated CatSperγ and CatSperδ proteins [@b58],[@b73], are restricted to the testis and localised to the principle piece of sperm tail.

Subunits
========

  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------- ------------------------- -------------------------
  Nomenclature                 CatSper1                                                                                                                                                                                                                                                                                                                                         CatSper2                  CatSper3                  CatSper4
  HGNC, UniProt                CATSPER1, Q8NEC5                                                                                                                                                                                                                                                                                                                                 CATSPER2, Q96P56          CATSPER3, Q86XQ3          CATSPER4, Q7RTX7
  Activators                   CatSper1 is constitutively active, weakly facilitated by membrane depolarisation, strongly augmented by intracellular alkalinisation. In human, but not mouse, spermatozoa progesterone (EC~50~ ∼ 8 nM) also potentiates the CatSper current (I~CatSper~).                                                                                       --                        --                        --
  Channel Blockers (IC~50~)    NNC55-0396 (2x10^-6^ -- 1x10^-5^ M), ruthenium red (1x10^-5^ M), HC056456 (2x10^-5^ M), mibefradil (3x10^-5^ M), Cd2+ (2x10^-4^ M), Ni2+ (3x10^-4^ M)                                                                                                                                                                                            --                        --                        --
  Functional characteristics   Calcium selective ion channel (Ba^2+^\>Ca^2+^\>\>Mg^2+^\>\>Na^+^); quasilinear monovalent cation current in the absence of extracellular divalent cations; alkalinization shifts the voltage-dependence of activation towards negative potentials \[V~½~ @ pH 6.0 = +87 mV (mouse); V~½~ @ pH 7.5 = +11mV (mouse) or pH 7.4 = +85 mV (human)\]   Required for I~CatSper~   Required for I~CatSper~   Required for I~CatSper~
  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------- ------------------------- -------------------------

Comments
========

CatSper channel subunits expressed singly, or in combination, fail to functionally express in heterologous expression systems [@b70],[@b71]. The properties of CatSper1 tabulated above are derived from whole cell voltage-clamp recordings comparing currents endogenous to spermatozoa isolated from the *corpus epididymis* of wild-type and *Catsper1^(-/-)^* mice [@b62] and also mature human sperm [@b63],[@b72]. I~CatSper~ is also undetectable in the spermatozoa of *Catsper2^(-/-)^*, *Catsper3^(-/-)^*, or *Catsper4^(-/-)^* mice and CatSper 1 associates with CatSper 2, 3, or 4 in heterologous expression systems [@b69]. Moreover, targeted disruption of *Catsper1, 2, 3,* or *4* genes results in an identical phenotype in which spermatozoa fail to exhibit the hyperactive movement (whip-like flagellar beats) necessary for penetration of the egg *cumulus* and *zona pellucida* and subsequent fertilization. Such disruptions are associated with a deficit in alkalinization and depolarization-evoked Ca^2+^ entry into spermatozoa [@b56],[@b57],[@b69]. Thus, it is likely that the CatSper pore is formed by a heterotetramer of CatSpers1--4 [@b69] in association with the auxiliary subunits (β, γ, δ) that are also essential for function [@b58]. CatSper channels are required for the increase in intracellular Ca^2+^ concentration in sperm evoked by egg *zona pellucida* glycoproteins [@b74]. The driving force for Ca^2+^ entry is principally determined by a mildly outwardly rectifying K^+^ channel (KSper) that, like CatSpers, is activated by intracellular alkalinization [@b68]. Mouse KSper is encoded by *mSlo3*, a protein detected only in testis [@b67],[@b68],[@b75]. In human sperm, such alkalinization may result from the activation of H~v~1, a proton channel [@b64]. Mutations in CatSpers are associated with syndromic and non-syndromic male infertility [@b60]. In human ejaculated spermatozoa, progesterone (8,17\]. In addition, certain prostaglandins (*e.g.* PGF1α, PGE1) also potentiate CatSper mediated currents [@b63],[@b72].

Chloride channels
=================

Overview
--------

Chloride channels are a functionally and structurally diverse group of anion selective channels involved in processes including the regulation of the excitability of neurones, skeletal, cardiac and smooth muscle, cell volume regulation, transepithelial salt transport, the acidification of internal and extracellular compartments, the cell cycle and apoptosis (reviewed in [@b92]). Excluding the transmitter-gated GABA~A~ and glycine receptors (see separate tables), well characterised chloride channels can be classified as certain members of the voltage-sensitive ClC subfamily, calcium-activated channels, high (maxi) conductance channels, the cystic fibrosis transmembrane conductance regulator (CFTR) and volume regulated channels [@b155]. No official recommendation exists regarding the classification of chloride channels. Functional chloride channels that have been cloned from, or characterised within, mammalian tissues are listed with the exception of several classes of intracellular channels (*e.g.* CLIC) that are reviewed by in [@b96].

ClC family
==========

Overview
--------

The mammalian ClC family (reviewed in [@b77],[@b87],[@b92],[@b94],[@b108]) contains 9 members that fall, on the basis of sequence homology, into three groups; ClC-1, ClC-2, hClC-Ka (rClC-K1) and hClC-Kb (rClC-K2); ClC-3 to ClC-5, and ClC-6 and -7. ClC-1 and ClC-2 are plasma membrane chloride channels. ClC-Ka and ClC-Kb are also plasma membrane channels (largely expressed in the kidney and inner ear) when associated with barttin (BSND, Q8WZ55), a 320 amino acid 2TM protein [@b97]. The localisation of the remaining members of the ClC family is likely to be predominantly intracellular *in vivo*, although they may traffic to the plasma membrane in overexpression systems. Numerous recent reports indicate that ClC-4, ClC-5, ClC-6 and ClC-7 (and by inference ClC-3) function as Cl^-^/H^+^ antiporters (secondary active transport), rather than classical Cl^-^ channels [@b103],[@b114],[@b125],[@b134],[@b146]; reviewed in [@b77],[@b139]). It has recently been reported that the activity of ClC-5 as a Cl^-^/H^+^ exchanger is important for renal endocytosis [@b127]. Alternative splicing increases the structural diversity within the ClC family. The crystal structure of two bacterial ClC proteins has been described [@b95] and a eukaryotic ClC transporter (CmCLC) has recently been described at 3.5 Å resolution [@b99]. Each ClC subunit, with a complex topology of 18 intramembrane segments, contributes a single pore to a dimeric 'double-barrelled' ClC channel that contains two independently gated pores, confirming the predictions of previous functional and structural investigations (reviewed in [@b87],[@b94],[@b108],[@b139]). As found for ClC-4, ClC-5, ClC-6 and ClC-7, the prokaryotic ClC homologue (ClC-ec1) and CmCLC function as H^+^/Cl antiporters, rather than as ion channels [@b151],[@b99]. The generation of monomers from dimeric ClC-ec1 has firmly established that each ClC subunit is a functional unit for transport and that cross-subunit interaction is not required for Cl^-^/H^+^ exchange in ClC transporters [@b141].

Subunits
--------

  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  Nomenclature                 ClC-1                                                                                                                                                                                                                                                                                                                                                                                      ClC-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ClC-Ka                                                                                                                                                                                        ClC-Kb
  HGNC, UniProt                CLCN1, P35523                                                                                                                                                                                                                                                                                                                                                                              CLCN2, P51788                                                                                                                                                                                                                                                                                                                                                                                                                                                           CLCNKA, P51800                                                                                                                                                                                CLCNKB, P51801
  Endogenous activators        --                                                                                                                                                                                                                                                                                                                                                                                         arachidonic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                        --                                                                                                                                                                                            --
  Activators (EC~50~)          --                                                                                                                                                                                                                                                                                                                                                                                         lubiprostone, omeprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                niflumic acid (1x10^-5^ -- 1x10^-3^ M)                                                                                                                                                        niflumic acid (1x10^-5^ -- 1x10^-3^ M)
  Channel Blockers (IC~50~)    9-A-C, Cd2+, fenofibric acid, S-(-)CPB, S-(-)CPP, niflumic acid, Zn2+                                                                                                                                                                                                                                                                                                                      Cd2+, DPC, NPPB, Zn2+, GaTx2 (*K*~d~ 1.5x10^-11^ M) \[*voltage dependent*-100.0 mV\]                                                                                                                                                                                                                                                                                                                                                                                    3-phenyl-CPP, DIDS, niflumic acid (\>1x10^-3^ M)                                                                                                                                              3-phenyl-CPP, DIDS
  Functional characteristics   γ = 1--1.5 pS; voltage-activated (depolarization) (by fast gating of single protopores and a slower common gate allowing both pores to open simultaneously); inwardly rectifying; incomplete deactivation upon repolarization, ATP binding to cytoplasmic cystathionine β-synthetase related (CBS) domains inhibits ClC-1 (by closure of the common gate), depending on its redox status   γ = 2--3 pS; voltage-activated by membrane hyperpolarization by fast protopore and slow cooperative gating; channels only open negative to E~Cl~ resulting in steady-state inward rectification; voltage dependence modulated by permeant anions; activated by cell swelling, PKA, and weak extracellular acidosis; potentiated by SGK1; inhibited by phosphorylation by p34(cdc2)/cyclin B; cell surface expression and activity increased by association with Hsp90   γ = 26 pS; linear current-voltage relationship except at very negative potentials; no time dependence; inhibited by extracellular protons (p*K* = 7.1); potentiated by extracellular Ca^2+^   Bidirectional rectification; no time dependence; inhibited by extracellular protons; potentiated by extracellular Ca^2+^
  Comment                      CIC-1 is constitutively active                                                                                                                                                                                                                                                                                                                                                             CIC-2 is also activated by amidation                                                                                                                                                                                                                                                                                                                                                                                                                                    CIC-Ka is constitutively active (when co-expressed with barttin), and can be blocked by benzofuran derivatives                                                                                CIC-Kb is constitutively active (when co-expressed with barttin), and can be blocked by benzofuran derivatives
  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------

  ---------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                 ClC-3                                                                                                                                                                                                           ClC-4                                                                                                                                                                                                                                                                                                      ClC-5                                                                                                                                                                                                                                                                                                                                                                                        ClC-6                                                                                                    ClC-7
  HGNC, UniProt                CLCN3, P51790                                                                                                                                                                                                   CLCN4, P51793                                                                                                                                                                                                                                                                                              CLCN5, P51795                                                                                                                                                                                                                                                                                                                                                                                CLCN6, P51797                                                                                            CLCN7, P51798
  Channel Blockers (IC~50~)    phloretin (3x10^-5^ M)                                                                                                                                                                                          Zn2+ (5x10^-5^ M) [@b131], Cd2+ (6.8x10^-5^ M) [@b131]                                                                                                                                                                                                                                                     --                                                                                                                                                                                                                                                                                                                                                                                           DIDS (1x10^-3^ M)                                                                                        DIDS (4x10^-5^ M) [@b149], NS5818 (5.2x10^-5^ M) [@b149], NPPB (1.56x10^-4^ M) [@b149]
  Functional characteristics   Cl^-^/H^+^ antiporter [@b121]; pronounced outward rectification; slow activation, fast deactivation; activity enhanced by CaM kinase II; inhibited by intracellular Ins(3,4,5,6)P4 and extracellular acidosis   Cl^-^/H^+^ antiporter (2Cl^-^:1H^+^) [@b79],[@b134],[@b146]; extreme outward rectification; voltage-dependent gating with midpoint of activation at +73 mV [@b130]; rapid activation and deactivation; inhibited by extracellular acidosis; non-hydrolytic nucleotide binding required for full activity   Cl^-^/H^+^ antiporter (2Cl^-^:1H^+^) [@b134],[@b146],[@b151],[@b159]; extreme outward rectification; voltage-dependent gating with midpoint of activation of 116.0 mV; rapid activation and deactivation; potentiated and inhibited by intracellular and extracellular acidosis, respectively; ATP binding to cytoplasmic cystathionine β-synthetase related (CBS) domains activates ClC-5   Cl^-^/H^+^ antiporter (2Cl^-^:1H^+^) [@b125]; outward rectification, rapid activation and deactivation   Cl^-^/H^+^ antiporter (2Cl^-^:1H^+^) [@b103],[@b114],[@b149]; strong outward rectification; voltage-dependent gating with a threshold more positive than ∼ + 20 mV; very slow activation and deactivation
  Comment                      insensitive to the channel blockers DIDS, NPPB and tamoxifen (10 μM)                                                                                                                                            --                                                                                                                                                                                                                                                                                                         insensitive to the channel blockers DIDS (1 mM), DPC (1 mM), 9-A-C (2 mM), NPPB (0.5 mM) and niflumic acid (1 mM)                                                                                                                                                                                                                                                                            --                                                                                                       active when co-expressed with Ostm1
  ---------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

ClC channels display the permeability sequence Cl^-^ \> Br^-^ \> I^-^ (at physiological pH). ClC-1 has significant opening probability at resting membrane potential, accounting for 75% of the membrane conductance at rest in skeletal muscle, and is important for stabilization of the membrane potential. S-(-)CPP, 9-A-C and niflumic acid act intracellularly and exhibit a strongly voltage-dependent block with strong inhibition at negative voltages and relief of block at depolarized potentials ([@b115] and reviewed in [@b138]). Inhibition of ClC-2 by the peptide GaTx2, from *Leiurus quinquestriatus herbareus* venom, is likely to occur through inhibition of channel gating, rather than direct open channel blockade [@b153]. Although ClC-2 can be activated by cell swelling, it does not correspond to the VRAC channel (see below). Alternative potential physiological functions for ClC-2 are reviewed in [@b137]. Functional expression of human ClC-Ka and ClC-Kb requires the presence of barttin [@b97],[@b147] reviewed in [@b98]. The properties of ClC-Ka/barttin and ClC-Kb/barttin tabulated are those observed in mammalian expression systems: in oocytes the channels display time- and voltage-dependent gating. The rodent homologue (ClC-K1) of ClC-Ka demonstrates limited expression as a homomer, but its function is enhanced by barttin which increases both channel opening probablility in the physiological range of potentials [@b97],[@b101],[@b147] reviewed in [@b98]). ClC-Ka is approximately 5 to 6-fold more sensitive to block by 3-phenyl-CPP and DIDS than ClC-Kb, while newly synthesized benzofuran derivatives showed the same blocking affinity (\<10 μM) on both CLC-K isoforms [@b116]. The biophysical and pharmacological properties of ClC-3, and the relationship of the protein to the endogenous volume-regulated anion channel(s) VRAC [@b78],[@b105] are controversial and further complicated by the possibility that ClC-3 may function as both a Cl^-^/H^+^ exchanger and an ion channel [@b78],[@b134],[@b156]. The functional properties tabulated are those most consistent with the close structural relationship between ClC-3, ClC-4 and ClC-5. Activation of heterologously expressed ClC-3 by cell swelling in response to hypotonic solutions is disputed, as are many other aspects of its regulation. Dependent upon the predominant extracellular anion (*e.g.* SCN^-^ versus Cl^-^), CIC-4 can operate in two transport modes: a slippage mode in which behaves as an ion channel and an exchanger mode in which unitary transport rate is 10-fold lower [@b79]. Similar findings have been made for ClC-5 [@b158]. ClC-7 associates with a β subunit, Ostm1, which increases the stability of the former [@b112] and is essential for its function [@b114].

CFTR
====

Overview
--------

CFTR, a 12TM, ABC transporter-type protein, is a cAMP-regulated epithelial cell membrane Cl^-^ channel involved in normal fluid transport across various epithelia. Of the 1700 mutations identified in CFTR, the most common is the deletion mutant ΔF508 (a class 2 mutation) which results in impaired trafficking of CFTR and reduces its incorporation into the plasma membrane causing cystic fibrosis (reviewed in [@b88]). Channels carrying the ΔF508 mutation that do traffic to the plasma membrane demonstrate gating defects. Thus, pharmacological restoration the function of the ΔF508 mutant would require a compound that embodies 'corrector' (*i.e.* facilitates folding and trafficking to the cell surface) and 'potentiator' (*i.e.* promotes opening of channels at the cell surface) activities [@b88]. In addition to acting as an anion channel *per se*, CFTR may act as a regulator of several other conductances including inhibition of the epithelial Na channel (ENaC), calcium activated chloride channels (CaCC) and volume regulated anion channel (VRAC), activation of the outwardly rectifying chloride channel (ORCC), and enhancement of the sulphonylurea sensitivity of the renal outer medullary potassium channel (ROMK2), (reviewed in [@b126]). CFTR also regulates TRPV4, which provides the Ca^2+^ signal for regulatory volume decrease in airway epithelia [@b81]. The activities of CFTR and the chloride-bicarbonate exchangers SLC26A3 (DRA) and SLC26A6 (PAT1) are mutually enhanced by a physical association between the regulatory (R) domain of CFTR and the STAS domain of the SCL26 transporters, an effect facilitated by PKA-mediated phosphorylation of the R domain of CFTR [@b109].

Channels
--------

  -------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Activators (EC~50~)                                                                                                                                                                                                                                                                                                                     Channel Blockers (IC~50~)                                                                                                       Functional characteristics                                                                                                                                                                                                                                                                                                                                                                                                          Comment
  CFTR           CFTR, P13569    apigenin (Potentiation), capsaicin (Potentiation), CBIQ (Potentiation), felodipine (Potentiation), genistein (Potentiation), nimodipine (Potentiation), NS004 (Potentiation), phenylglycine-01 (Potentiation), SF-01 (Potentiation), UCCF-029 (Potentiation), UCCF-339 (Potentiation), UCCF-853 (Potentiation), VX-770 (Potentiation)   intracellular CFTRinh-172 (intracellular application prolongs mean closed time), GaTx1, glibenclamide, extracellular GlyH-101   γ = 6--10 pS; permeability sequence = Br^-^ ≥ Cl^-^ \> I^-^ \> F^-^, (P~I~/P~Cl~ = 0.1--0.85); slight outward rectification; phosphorylation necessary for activation by ATP binding at binding nucleotide binding domains (NBD)1 and 2; positively regulated by PKC and PKGII (tissue specific); regulated by several interacting proteins including syntaxin 1A, Munc18 and PDZ domain proteins such as NHERF (EBP50) and CAP70   UCCF-339, UCCF-029, apigenin and genistein are examples of flavones. UCCF-853 and NS004 are examples of benzimidazolones. CBIQ is an example of a benzoquinoline. felodipine and nimodipine are examples of 1,4-dihydropyridines. phenylglycine-01 is an example of a phenylglycine. SF-01 is an example of a sulfonamide. Malonic acid hydrazide conjugates are also CFTR channel blockers (see Verkman and Galietta, [@b135] [@b155])
  -------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
--------

In addition to the agents listed in the table, the novel small molecule, ataluren, induces translational read through of nonsense mutations in CFTR (reviewed in [@b150]). Corrector compounds that aid the folding of DF508CFTR to increase the amount of protein expressed and potentially delivered to the cell surface include VX-532 (which is also a potentiator), VRT-325, KM11060, Corr-3a and Corr-4a see [@b155] for details and structures of Corr-3a and Corr-4a). Inhibition of CFTR by intracellular application of the peptide GaTx1, from *Leiurus quinquestriatus herbareus* venom, occurs preferentially for the closed state of the channel [@b102]. CFTR contains two cytoplasmic nucleotide binding domains (NBDs) that bind ATP. A single open-closing cycle is hypothesised to involve, in sequence: binding of ATP at the N-terminal NBD1, ATP binding to the C-terminal NBD2 leading to the formation of an intramolecular NBD1-NBD2 dimer associated with the open state, and subsequent ATP hydrolysis at NBD2 facilitating dissociation of the dimer and channel closing, and the initiation of a new gating cycle [@b80],[@b122]. Phosphorylation by PKA at sites within a cytoplasmic regulatory (R) domain facilitates the interaction of the two NBD domains. PKC (and PKGII within intestinal epithelial cells via guanylinstimulated cGMP formation) positively regulate CFTR activity.

Calcium activated chloride channel
==================================

Overview
--------

Chloride channels activated by intracellular calcium (CaCC) are widely expressed in excitable and non-excitable cells where they perform diverse functions [@b106]. The molecular nature of CaCC has been uncertain with both *CLCA*, *TWEETY* and *BEST* genes having been considered as likely candidates [@b92],[@b107],[@b117]. It is now accepted that CLCA expression products are unlikely to form channels *per se* and probably function as cell adhesion proteins, or are secreted [@b133]. Similarly, *TWEETY* gene products do not recapictulate the properties of endogenous CaCC. The bestrophins encoded by genes *BEST1-4* have a topology more consistent with ion channels [@b107] and form chloride channels that are activated by physiological concentrations of Ca^2+^, but whether such activation is direct is not known [@b107]. However, currents generated by bestrophin over-expression do not resemble native CaCC currents. The evidence for and against bestrophin proteins forming CaCC is critically reviewed by Duran *et al*. in their 2010 paper [@b92]. Recently, a new gene family, TMEM16 (anoctamin) consisting of 10 members (TMEM16A-K; anoctamin 1--10) has been identified and there is firm evidence that some of these members form chloride channels [@b91],[@b110]. TMEM16A (anoctamin 1; Ano 1) produces Ca^2+^-activated Cl^-^ currents with kinetics similar to native CaCC currents recorded from different cell types [@b86],[@b142],[@b148],[@b157]. Knockdown of TMEM16A greatly reduces currents mediated by calcium-activated chloride channels in submandibular gland cells [@b157] and smooth muscle cells from pulmonary artery [@b118]. In TMEM16A^(-/-)^ mice secretion of Ca^2+^-dependent Cl^-^ secretion by several epithelia is reduced [@b132],[@b142]. Alternative splicing regulates the voltage- and Ca^2+^- dependence of TMEM16A and such processing may be tissue-specific manner and thus contribute to functional diversity [@b100]. There are also reports that TMEM16B (anoctamin 2; Ano 2) supports CaCC activity (*e.g*. [@b135]) and in TMEM16B^(-/-)^ mice Ca-activated Cl^-^ currents in the main olfactory epithelium (MOE) and in the vomeronasal organ are virtually absent [@b85].

Subunits
--------

  -------------- --------------- -------------------------------- -------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Endogenous activators (EC~50~)   Endogenous channel blockers (IC~50~)   Channel Blockers (IC~50~)                                                                             Functional characteristics
  CaCC           ANO1, Q5XXA6    intracellular Ca2+               Ins(3,4,5,6)P4                         9-A-C, DCDPC, DIDS, flufenamic acid, fluoxetine, mibefradil, niflumic acid, NPPB, SITS, tannic acid   γ = 0.5--5 pS; permeability sequence, SCN^-^ \> NO~3~^-^\> I^-^ \> Br^-^ \> Cl^-^ \> F^-^; relative permeability of SCN^-^:Cl^-^ ∼8. I-:Cl^-^ ∼3, aspartate:Cl^-^ ∼0.15, outward rectification (decreased by increasing \[Ca^2+^\]~i~); sensitivity to activation by \[Ca^2+^\]~i~ decreased at hyperpolarized potentials; slow activation at positive potentials (accelerated by increasing \[Ca^2+^\]~i~); rapid deactivation at negative potentials, deactivation kinetics modulated by anions binding to an external site; modulated by redox status
  -------------- --------------- -------------------------------- -------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
--------

Blockade of I~Cl(Ca)~ by niflumic acid, DIDS and 9-A-C is voltage-dependent whereas block by NPPB is voltage-independent [@b106]. Extracellular niflumic acid; DCDPC and 9-A-C (but not DIDS) exert a complex effect upon I~Cl(Ca)~ in vascular smooth muscle, enhancing and inhibiting inwardly and outwardly directed currents in a manner dependent upon \[Ca^2+^\]~i~ (see [@b113] for summary). Considerable crossover in pharmacology with large conductance Ca^2+^-activated K^+^ channels also exists (see [@b104] for overview). Two novel compounds, CaCC~inh~-A01 and CaCC~inh~-B01 have recently been identified as blockers of calcium-activated chloride channels in T84 human intestinal epithelial cells [@b89] for structures). Significantly, other novel compounds totally block currents mediated by TMEM116A, but have only a modest effect upon total current mediated by CaCC native to T84 cells or human bronchial epithelial cells, suggesting that TMEM16A is not the predominant CaCC in such cells [@b124]. CaMKII modulates CaCC in a tissue dependent manner (reviewed by [@b106],[@b113]). CaMKII inhibitors block activation of I~Cl(Ca)~ in T84 cells but have no effect in parotid acinar cells. In tracheal and arterial smooth muscle cells, but not portal vein myocytes, inhibition of CaMKII reduces inactivation of I~Cl(Ca)~. Intracellular Ins(3,4,5,6)P4may act as an endogenous negative regulator of CaCC channels activated by Ca^2+^, or CaMKII. Smooth muscle CaCC are also regulated positively by Ca^2+^-dependent phosphatase, calcineurin (see [@b113] for summary).

Maxi chloride channel
=====================

Overview
--------

Maxi Cl^-^ channels are high conductance, anion selective, channels initially characterised in skeletal muscle and subsequently found in many cell types including neurones, glia, cardiac muscle, lymphocytes, secreting and absorbing epithelia, macula densa cells of the kidney and human placenta syncytiotrophoblasts [@b144]. The physiological significance of the maxi Cl^-^ channel is uncertain, but roles in cell volume regulation and apoptosis have been claimed. Evidence suggests a role for maxi Cl^-^ channels as a conductive pathway in the swelling-induced release of ATP from mouse mammary C127i cells that may be important for autocrine and paracrine signalling by purines [@b93],[@b143]. A similar channel mediates ATP release from macula densa cells within the thick ascending of the loop of Henle in response to changes in luminal NaCl concentration [@b83]. A family of human high conductance Cl^-^ channels (TTYH1-3) that resemble Maxi Cl^-^ channels has been cloned [@b152], but alternatively, Maxi Cl^-^ channels have also been suggested to correspond to the voltage-dependent anion channel, VDAC, expressed at the plasma membrane [@b82],[@b128].

Channels
--------

  -------------- --------------------------------------------------------------------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   Activators (EC~50~)                                                                                                               Endogenous channel blockers (IC~50~)   Channel Blockers (IC~50~)                                                                                                         Functional characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Comment
  Maxi Cl-       extracellular chlorpromazine, cytosolic GTPγS, extracellular tamoxifen, extracellular toremifene, extracellular triflupromazine   intracellular arachidonic acid         DPC, extracellular Gd3+, SITS, DIDS (4x10^-5^ M) [@b149], extracellular Zn2+ (5x10^-5^ M) [@b131], NPPB (1.56x10^-4^ M) [@b149]   γ = 280--430 pS (main state); permeability sequence, I \> Br \> Cl \> F \> gluconate (P~CI~P~Cl~ = ∼1.5); ATP is a voltage dependent permeant blocker of single channel activity (P~ATP~/P~Cl~ = 0.08--0.1); channel activity increased by patch-excision; channel opening probability (at steady-state) maximal within approximately ± 20 mV of 0 mV, opening probability decreased at more negative and (commonly) positive potentials yielding a bell-shaped curve; channel conductance and opening probability regulated by annexin 6   Maxi Cl^-^ is also activated by G protein-coupled receptors and cell swelling. tamoxifen and toremifene are examples of triphenylethylene anti-oestrogens
  -------------- --------------------------------------------------------------------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
--------

Differing ionic conditions may contribute to variable estimates of γ reported in the literature. Inhibition by arachidonic acid (and cis-unsaturated fatty acids) is voltage-independent, occurs at an intracellular site, and involves both channel shut down (K*~d~* = 4--5 μM) and a reduction of γ (K*~d~* = 13--14 μM). Blockade of channel activity by SITS, DIDS, Gd^3+^ and arachidonic acid is paralleled by decreased swelling-induced release of ATP [@b93],[@b143]. Channel activation by anti-oestrogens in whole cell recordings requires the presence of intracellular nucleotides and is prevented by pre-treatment with 17β-estradiol, dibutyryl cAMP, or intracellular dialysis with GDPβS [@b90]. Activation by tamoxifen is suppressed by low concentrations of okadaic acid, suggesting that a dephosphorylation event by protein phosphatase PP2A occurs in the activation pathway [@b90]. In contrast, 17β-estradiol and tamoxifen appear to directly inhibit the maxi Cl^-^ channel of human placenta reconstituted into giant liposomes and recorded in excised patches [@b140].

Volume regulated chloride channels
==================================

Overview
--------

Volume activated chloride channels (also termed VSOAC, volume-sensitive organic osmolyte/anion channel; VRC, volume regulated channel and VSOR, volume expansion-sensing outwardly rectifying anion channel) participate in regulatory volume decrease (RVD) in response to cell swelling. VRAC may also be important for several other processes including the regulation of membrane excitability, transcellular Cl^-^ transport, angiogenesis, cell proliferation, necrosis, apoptosis, glutamate release from astrocytes, insulin (INS, P01308) release from pancreatic β cells and resistance to the anti-cancer drug, cisplatin (reviewed by [@b84],[@b123],[@b126],[@b129]). VRAC may not be a single entity, but may instead represent a number of different channels that are expressed to a variable extent in different tissues and are differentially activated by cell swelling. In addition to ClC-3 expression products (see above) several former VRAC candidates including *MDR1* P-glycoprotein, Icln, Band 3 anion exchanger and phospholemman are also no longer considered likely to fulfil this function (see reviews [@b126],[@b145]).

Channels
--------

  -------------- --------------------- -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   Activators (EC~50~)   Endogenous channel blockers (IC~50~)   Channel Blockers (IC~50~)                                                                                                                                                                   Functional characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Comment
  VRAC           GTPγS                 arachidonic acid, extracellular Mg2+   1,9-dideoxyforskolin, 9-A-C, carbenoxolone, clomiphene, DCPIB, diBA-(5)-C4, DIDS, gossypol, IAA-94, mefloquine, mibefradil, nafoxidine, NDGA, NPPB, NS3728, quinidine, quinine, tamoxifen   γ = 10--20 pS (negative potentials), 50--90 pS (positive potentials); permeability sequence SCN \> I \> NO^3-^ \>Br^-^ \> Cl^-^ \> F^-^ \> gluconate; outward rectification due to voltage dependence of γ; inactivates at positive potentials in many, but not all, cell types; time dependent inactivation at positive potentials; intracellular ionic strength modulates sensitivity to cell swelling and rate of channel activation; rate of swelling-induced activation is modulated by intracellular ATP concentration; ATP dependence is independent of hydrolysis and modulated by rate of cell swelling; inhibited by increased intracellular free Mg^2^+ concentration; swelling induced activation of several intracellular signalling cascades may be permissive of, but not essential to, the activation of VRAC including: the Rho-Rho kinase-MLCK; Ras-Raf-MEK-ERK; PIK3-NOX-H~2~O~2~ and Src-PLCγ-Ca^2^+ pathways; regulation by PKCα required for optimal activity; cholesterol depletion enhances activity; activated by direct stretch of β1-integrin   VRAC is also activated by cell swelling and low intracellular ionic strength. VRAC is also blocked by chromones, extracellular nucleotides and nucleoside analogues
  -------------- --------------------- -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
--------

In addition to conducting monovalent anions, in many cell types the activation of VRAC by a hypotonic stimulus can allow the efflux of organic osmolytes such as amino acids and polyols that may contribute to RVD.

Other chloride channels
-----------------------

In addition to some intracellular chloride channels that are not considered here, plasma membrane channels other than those listed have been functionally described. Many cells and tissues contain outwardly rectifying chloride channels (ORCC) that may correspond to VRAC active under isotonic conditions. A cAMP-activated Cl^-^ channel that does not correspond to CFTR has been described in intestinal Paneth cells [@b154]. A Cl channel activated by cGMP with a dependence on raised intracellular Ca^2+^ has been recorded in various vascular smooth muscle cells types, which has a pharmacology and biophysical characteristics very different from the 'conventional' CaCC [@b119],[@b136]. It has been proposed that bestrophin-3 (BEST3, Q8N1M1) is an essential component of the cGMP-activated channel [@b120]. A proton-activated, outwardly rectifying anion channel has also been described [@b111].

Connexins and Pannexins
=======================

Overview
--------

Gap junctions are essential for many physiological processes including cardiac and smooth muscle contraction, regulation of neuronal excitability and epithelial electrolyte transport [@b162]--[@b164]. Gap junction channels allow the passive diffusion of molecules of up to 1,000 Daltons which can include nutrients, metabolites and second messengers (such as IP~3~) as well as cations and anions. 21 connexin genes (Cx23, Cx25, Cx26, Cx30, Cx30.2, Cx30.3, Cx31, Cx31.1, Cx31.9, Cx32, Cx36, Cx37, Cx40, Cx40.1, Cx43, Cx45, Cx46, Cx47, Cx50, Cx59, Cx62) and 3 pannexin genes (Px1, Px2, Px3; which are structurally related to the invertebrate innexin genes) code for gap junction proteins (provisional nomenclature) in humans. Each connexin gap junction comprises 2 hemichannels or 'connexons' which are themselves formed from 6 connexin molecules. The various connexins have been observed to combine into both homomeric and heteromeric combinations, each of which may exhibit different functional properties. It is also suggested that individual hemichannels formed by a number of different connexins might be functional in at least some cells [@b165]. Connexins have a common topology, with four α-helical transmembrane domains, two extracellular loops, a cytoplasmic loop, and N- and C-termini located on the cytoplasmic membrane face. In mice, the most abundant connexins in electrical synapses in the brain seem to be Cx36, Cx45 and Cx57 [@b168]. Mutations in connexin genes are associated with the occurrence of a number of pathologies, such as peripheral neuropathies, cardiovascular diseases and hereditary deafness. The pannexin genes Px1 and Px2 are widely expressed in the mammalian brain [@b169]. Like the connexins, at least some of the pannexins can form hemichannels [@b162],[@b166].

Subunits
========

  ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Nomenclature            Cx23, Cx25, Cx26, Cx30, Cx30.2, Cx30.3, Cx31, Cx31.1, Cx31.9, Cx32, Cx36, Cx37, Cx40, Cx40.1, Cx43, Cx45, Cx46, Cx47, Cx50, Cx59, Cx62                                                                                                                                                                  Px1, Px2, Px3
  HGNC, UniProt           GJE1, A6NN92; GJB7, Q6PEY0; GJB2, P29033; GJB6, O95452; GJC3, Q8NFK1; GJB4, Q9NTQ9; GJB3, O75712; GJB5, O95377; GJD3, Q8N144; GJB1, P08034; GJD2, Q9UKL4; GJA4, P35212; GJA5, P36382; GJD4, Q96KN9; GJA1, P17302; GJC1, P36383; GJA3, Q9Y6H8; GJC2, Q5T442; GJA8, P48165; GJA9, P57773; GJA10, Q969M2   PANX1, Q96RD7; PANX2, Q96RD6; PANX3, Q96QZ0
  Endogenous inhibitors   extracellular Ca2+ (blocked by raising external Ca^2+^)                                                                                                                                                                                                                                                 --
  Inhibitors              carbenoxolone, flufenamic acid, octanol                                                                                                                                                                                                                                                                 carbenoxolone, flufenamic acid (little block by flufenamic acid)
  Comment                 --                                                                                                                                                                                                                                                                                                      The pannexins are unaffected by raising external Ca^2+^
  ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------

Comments
========

Connexins are most commonly named according to their molecular weights, so, for example, Cx23 is the connexin protein of 23 kDa. This can cause confusion when comparing between species -- for example, the mouse connexin Cx57 is orthologous to the human connexin Cx62. No natural toxin or specific inhibitor of junctional channels has been identified yet however two compounds often used experimentally to block connexins are carbenoxolone and flufenamic acid [@b167]. At least some pannexin hemichannels are more sensitive to carbenoxolone than connexins but much less sensitive to flufenamic acid [@b161]. It has been suggested that 2-aminoethoxydiphenyl borate (2-APB) may be a more effective blocker of some connexin channel subtypes (Cx26, Cx30, Cx36, Cx40, Cx45, Cx50) compared to others (Cx32, Cx43, Cx46, [@b160]).

Cyclic nucleotide-regulated channels
====================================

Overview
--------

Cyclic nucleotide-gated (CNG) channels are responsible for signalling in the primary sensory cells of the vertebrate visual and olfactory systems. A standardised nomenclature for CNG channels has been proposed by the NC-IUPHAR subcommittee on voltage-gated ion channels [@b176].

CNG channels are voltage-independent cation channels formed as tetramers. Each subunit has 6TM, with the pore-forming domain between TM5 and TM6. CNG channels were first found in rod photoreceptors [@b175],[@b177], where light signals through rhodopsin and transducin to stimulate phosphodiesterase and reduce intracellular cGMP level. This results in a closure of CNG channels and a reduced 'dark current'. Similar channels were found in the cilia of olfactory neurons [@b178] and the pineal gland [@b174]. The cyclic nucleotides bind to a domain in the C terminus of the subunit protein: other channels directly binding cyclic nucleotides include HCN, eag and certain plant potassium channels.

Subunits
========

  ---------------------------- -------------------------------------- ---------------------------------- ----------------------------------- --------------- --------------- ---------------
  Nomenclature                 CNGA1                                  CNGA2                              CNGA3                               CNGA4           CNGB1           CNGB3
  HGNC, UniProt                CNGA1, P29973                          CNGA2, Q16280                      CNGA3, Q16281                       CNGA4, Q8IV77   CNGB1, Q14028   CNGB3, Q9NQW8
  Activators                   cGMP (EC~50~ ∼ 30 μM) \>\> cAMP        cGMP ∼ cAMP (EC~50~ ∼ 1 μM)        cGMP (EC~50~ ∼ 30 μM) \>\> cAMP     --              --              --
  Inhibitors                   L-(cis)-diltiazem                      --                                 L-(cis)-diltiazem                   --              --              --
  Functional characteristics   γ = 25--30 pS, *P*~Ca~/*P*~Na~ = 3.1   γ = 35 pS, *P*~Ca~/*P*~Na~ = 6.8   γ = 40 pS, *P*~Ca~/*P*~Na~ = 10.9   --              --              --
  ---------------------------- -------------------------------------- ---------------------------------- ----------------------------------- --------------- --------------- ---------------

Comments
========

CNGA1, CNGA2 and CNGA3 express functional channels as homomers. Three additional subunits CNGA4 (Q8IV77), CNGB1 (Q14028) and CNGB3 (Q9NQW8) do not, and are referred to as auxiliary subunits. The subunit composition of the native channels is believed to be as follows. Rod: CNGA1~3~/CNGB1a; Cone: CNGA3~2~/CNGB3~2~; Olfactory neurons: CNGA2~2~/CNGA4/CNGB1b [@b180]--[@b184].

Hyperpolarisation-activated, cyclic nucleotide-gated (HCN)
==========================================================

The hyperpolarisation-activated, cyclic nucleotide-gated (HCN) channels are cation channels that are activated by hyperpolarisation at voltages negative to ∼-50 mV. The cyclic nucleotides cAMP and cGMP directly activate the channels and shift the activation curves of HCN channels to more positive voltages, thereby enhancing channel activity. HCN channels underlie pacemaker currents found in many excitable cells including cardiac cells and neurons [@b173],[@b179]. In native cells, these currents have a variety of names, such as *I*~h~, *I*~q~ and *I*~f~. The four known HCN channels have six transmembrane domains and form tetramers. It is believed that the channels can form heteromers with each other, as has been shown for HCN1 and HCN4 [@b170]. A standardised nomenclature for HCN channels has been proposed by the NC-IUPHAR subcommittee on voltage-gated ion channels [@b176].

  --------------- -------------------------- ------------------------- ------------------------- -------------------------
  Nomenclature    HCN1                       HCN2                      HCN3                      HCN4
  HGNC, UniProt   HCN1, O60741               HCN2, Q9UL51              HCN3, Q9P1Z3              HCN4, Q9Y3Q4
  Activators      cAMP \> cGMP (both weak)   cAMP \> cGMP              --                        cAMP \> cGMP
  Inhibitors      Cs+, ivabradine, ZD7288    Cs+, ivabradine, ZD7288   Cs+, ivabradine, ZD7288   Cs+, ivabradine, ZD7288
  --------------- -------------------------- ------------------------- ------------------------- -------------------------

Comments
========

HCN channels are permeable to both Na^+^ and K^+^ ions, with a Na^+^/K^+^ permeability ratio of about 0.2. Functionally, they differ from each other in terms of time constant of activation with HCN1 the fastest, HCN4 the slowest and HCN2 and HCN3 intermediate. The compounds ZD7288 [@b171] and ivabradine [@b172] have proven useful in identifying and studying functional HCN channels in native cells. zatebradine and cilobradine are also useful blocking agents.

Epithelial sodium channels (ENaC)
=================================

Overview
--------

The epithelial sodium channels (ENaC) mediates sodium reabsorption in the aldosterone-sensitive distal part of the nephron and the collecting duct of the kidney. ENaC is found on other tight epithelial tissues such as the airways, distal colon and exocrine glands. ENaC activity is tightly regulated in the kidney by aldosterone, angiotensin II (AGT, P01019), vasopressin, insulin (INS, P01308) and glucocorticoids; this fine regulation of ENaC is essential to maintain sodium balance between daily intake and urinary excretion of sodium, circulating volume and blood pressure. ENaC expression is also vital for clearance of foetal lung fluid, and to maintain air-surface-liquid [@b195],[@b199]. Sodium reabsorption is suppressed by the 'potassium-sparing' diuretics amiloride and triamterene. ENaC is a heteromultimeric channel made of homologous α β and γ subunits. The primary structure of αENaC subunit was identified by expression cloning [@b188]; β and γ ENaC were identified by functional complementation of the α subunit [@b189]. Each ENaC subunit contains 2 TM α helices connected by a large extracellular loop and short cytoplasmic amino- and carboxy-termini. The stoichiometry of the epithelial sodium channel in the kidney and related epithelia is, by homology with the structurally related channel ASIC1a, thought to be a heterotrimer of 1α:1β:1γ subunits [@b193].

Channels
========

  -------------- ------------------------ ------------------------------ ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   Subunits                 Activators (EC~50~)            Channel Blockers (IC~50~)                                                                                                       Functional characteristics
  ENaCαβγ        ENaC α, ENaC β, ENaC γ   S3969 (1.2x10^-6^ M) [@b200]   P552-02 (7.6x10^-9^ M), benzamil (∼1x10^-8^ M), amiloride (1x10^-7^ -- 2x10^-7^ M), triamterene (∼5x10^-6^ M) [@b189],[@b196]   γ ≈ 4--5 pS, P~Na~/P~K~ \> 20; tonically open at rest; expression and ion flux regulated by circulating aldosterone-mediated changes in gene transcription. The action of aldosterone, which occurs in 'early' (1.5--3 h) and 'late' (6--24 hr) phases is competitively antagonised by spironolactone, its active metabolites and eplerenone. Glucocorticoids are important functional regulators in lung/airways and this control is potentiated by thyroid hormone; but the mechanism underlying such potentiation is unclear [@b185],[@b206],[@b209]. The density of channels in the apical membrane, and hence G~Na~, can be controlled *via* both serum and glucocorticoid-regulated kinases (SGK1, 2 and 3) [@b190],[@b191] and *via* cAMP/PKA [@b203]; and these protein kinases appear to act by inactivating Nedd-4/2, a ubiquitin ligase that normally targets the ENaC channel complex for internalization and degradation [@b186],[@b190]. ENaC is constitutively activated by soluble and membrane-bound serine proteases, such as furin, prostasin (CAP1), plasmin and elastase [@b197],[@b198],[@b204],[@b207],[@b208]. The activation of ENaC by proteases is blocked by a protein, SPLUNC1, secreted by the airways and which binds specifically to ENaC to prevent its cleavage [@b192]. Pharmacological inhibitors of proteases (*e.g*. camostat acting upon prostasin) reduce the activity of ENaC [@b202]. Phosphatidylinositides such as PtIns(4,5)P~2~ and PtIns(3,4,5)P~3~) stabilise channel gating probably by binding to the β and γ ENaC subunits, respectively [@b201],[@b205], whilst C terminal phosphorylation of β and γ-ENaC by ERK1/2 has been reported to inhibit the withdrawal of the channel complex from the apical membrane [@b212]. This effect may contribute to the cAMP-mediated increase in sodium conductance.
  -------------- ------------------------ ------------------------------ ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Data in the table refer to the αβγ heteromer. There are several human diseases resulting from mutations in ENaC subunits. Liddle\'s syndrome (including features of salt-sensitive hypertension and hypokalemia), is associated with gain of function mutations in the β and γ subunits leading to defective ENaC ubiquitylation and increased stability of active ENaC at the cell surface [@b208],[@b210],[@b211]. Enzymes that deubiquitylate ENaC increase its function *in vivo*. Pseudohypoaldosteronism type 1 (PHA-1) can occur through either mutations in the gene encoding the mineralocorticoid receptor, or loss of function mutations in genes encoding ENaC subunits [@b187]. Regulation of ENaC by phosphoinositides may underlie insulin (INS, P01308)-evoked renal Na^+^ retention that can complicate the clinical management of type 2 diabetes using insulin-sensitizing thiazolidinedione drugs [@b194].

IP3 receptor
============

Overview
--------

The inositol 1,4,5-trisphosphate (IP~3~) receptors (provisional nomenclature) are ligand-gated Ca^2+^-release channels on intracellular Ca^2+^ store sites (such as the endoplasmic reticulum). They are responsible for the mobilization of intracellular Ca^2+^ stores and play an important role in intracellular Ca^2+^ signalling in a wide variety of cell types. Three different gene products (types I--III) have been isolated, which assemble as large tetrameric structures. IP~3~ receptors are closely associated with certain proteins: calmodulin (CALM2, CALM3, CALM1, P62158) and FKBP (and calcineurin via FKBP). They are phosphorylated by PKA, PKC, PKG and CaMKII.

Subunits
========

  --------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  Nomenclature                      IP3R1                                                                                                                   IP3R2                                                                                                                   IP3R3
  HGNC, UniProt                     ITPR1, Q14643                                                                                                           ITPR2, Q14571                                                                                                           ITPR3, Q14573
  Endogenous activators (EC~50~)    cytosolic ATP (\< mM range), IP3 (endogenous; nM - μM range), cytosolic Ca2+ (Concentration range = \< 7.5x10^-4^ M)    cytosolic Ca2+ (nM range), IP3 (endogenous; nM - μM range)                                                              cytosolic Ca2+ (nM range), IP3 (endogenous; nM - μM range)
  Activators (EC~50~)               adenophostin A (pharmacological; nM range), Ins(2,4,5)P3 (pharmacological; also activated by other InsP~3~ analogues)   adenophostin A (pharmacological; nM range), Ins(2,4,5)P3 (pharmacological; also activated by other InsP~3~ analogues)   --
  Endogenous antagonists (IC~50~)   heparin (μg/ml)                                                                                                         heparin (μg/ml)                                                                                                         heparin (μg/ml)
  Antagonists (IC~50~)              caffeine (mM range), decavanadate (μM range), PIP2 (μM range), xestospongin C (μM range)                                decavanadate (μM range)                                                                                                 decavanadate (μM range)
  Functional characteristics        Ca^2+^: (P~Ba~/P~K~ ∼6) single-channel conductance, ∼70 pS (50 mM Ca^2+^)                                               Ca^2+^: single-channel conductance, ∼70 pS (50 mM Ca^2+^), ∼390 pS (220 mM Cs^+^)                                       Ca^2+^: single-channel conductance, ∼88 pS (55 mM Ba^2+^)
  Comment                           IP~3~ R1 is also antagonised by calmodulin at high cytosolic Ca^2+^ concentrations                                      --                                                                                                                      --
  --------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------

Comments
========

The absence of a modulator of a particular isoform of receptor indicates that the action of that modulator has not been determined, not that it is without effect.

Potassium channels
==================

Overview
--------

Potassium channels are fundamental regulators of excitability. They control the frequency and the shape of action potential waveform, the secretion of hormones and neurotransmitters and cell membrane potential. Their activity may be regulated by voltage, calcium and neurotransmitters (and the signalling pathways they stimulate). They consist of a primary pore-forming a subunit often associated with auxiliary regulatory subunits. Since there are over 70 different genes encoding K channels α subunits in the human genome, it is beyond the scope of this guide to treat each subunit individually. Instead, channels have been grouped into families and subfamilies based on their structural and functional properties. The three main families are the 2TM (two transmembrane domain), 4TM and 6TM families. A standardised nomenclature for potassium channels has been proposed by the NC-IUPHAR subcommittees on potassium channels [@b213]--[@b216].

Inwardly rectifying potassium channels
======================================

Overview
--------

The 2TM domain family of K channels are also known as the inward-rectifier K channel family. This family includes the strong inward-rectifier K channels (K~IR~2.x), the G-protein-activated inward-rectifier K channels (K~IR~3.x) and the ATP-sensitive K channels (K~IR~6.x, which combine with sulphonylurea receptors (SUR)). The pore-forming a subunits form tetramers, and heteromeric channels may be formed within subfamilies (*e.g.* K~IR~3.2 with K~IR~3.3).

Subunits
--------

  ---------------------------- -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- -------------------------- ---------------------------------------------- --------------------------
  Nomenclature                 Kir1.1                     Kir2.1, Kir2.2, Kir2.3, Kir2.4                                                                                                                                                                                                   Kir3.1, Kir3.2, Kir3.3, Kir3.4                                                                                                                       Kir4.1, Kir4.2                   Kir5.1                     Kir6.1, Kir6.2                                 Kir7.1
  HGNC, UniProt                KCNJ1, P48048              KCNJ2, P63252; KCNJ12, Q14500; KCNJ4, P48050; KCNJ14, Q9UNX9                                                                                                                                                                     KCNJ3, P48549; KCNJ6, P48051; KCNJ9, Q92806; KCNJ5, P48544                                                                                           KCNJ10, P78508; KCNJ15, Q99712   KCNJ16, Q9NPI9             KCNJ8, Q15842; KCNJ11, Q14654                  KCNJ13, O60928
  Endogenous inhibitors        --                         intracellular Mg2+                                                                                                                                                                                                               --                                                                                                                                                   --                               --                         --                                             --
  Endogenous activators        --                         --                                                                                                                                                                                                                               PIP2                                                                                                                                                 --                               --                         --                                             --
  Associated subunits          --                         --                                                                                                                                                                                                                               --                                                                                                                                                   --                               --                         SUR1, SUR2A, SUR2B                             --
  Activators                   --                         --                                                                                                                                                                                                                               --                                                                                                                                                   --                               --                         cromakalim, diazoxide, minoxidil, nicorandil   --
  Inhibitors                   --                         --                                                                                                                                                                                                                               --                                                                                                                                                   --                               --                         glibenclamide, tolbutamide                     --
  Functional characteristics   Inward-rectifier current   IK~1~ in heart, 'strong' inward--rectifier current                                                                                                                                                                               G-protein-activated inward-rectifier current                                                                                                         Inward-rectifier current         Inward-rectifier current   ATP-sensitive, inward-rectifier current        Inward-rectifier current
  Comment                      --                         K~IR~2.1 is also inhibited by intracellular polyamines, K~IR~2.2 is also inhibited by intracellular polyamines, K~IR~2.3 is also inhibited by intracellular polyamines, K~IR~2.4 is also inhibited by intracellular polyamines   K~IR~3.1 is also activated by G~βγ~, K~IR~3.2 is also activated by G~βγ~, K~IR~3.3 is also activated by G~βγ~, K~IR~3.4 is also activated by G~βγ~   --                               --                         --                                             --
  ---------------------------- -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- -------------------------- ---------------------------------------------- --------------------------

Two-P potassium channels
========================

Overview
--------

The 4TM family of K channels are thought to underlie many leak currents in native cells. They are open at all voltages and regulated by a wide array of neurotransmitters and biochemical mediators. The primary pore-forming αsubunit contains two pore domains (indeed, they are often referred to as two-pore domain K channels or K2P) and so it is envisaged that they form functional dimers rather than the usual K channel tetramers. There is some evidence that they can form heterodimers within subfamilies (*e.g.* K~2P~3.1 with K~2P~9.1). There is no current, clear, consensus on nomenclature of 4TM K channels, nor on the division into subfamilies [@b213]. The suggested division into subfamilies, below, is based on similarities in both structural and functional properties within subfamilies.

Subunits
--------

  -------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------------------- --------------------
  Nomenclature                     K2P1.1, K2P6.1, K2P7.1                                                                                          K2P2.1, K2P10.1, K2P4.1                                                                                                                                                               K2P3.1, K2P9.1, K2P15.1                                                                                                                                    K2P16.1, K2P5.1, K2P17.1                                                                                                      K2P13.1, K2P12.1                 K2P18.1
  HGNC, UniProt                    KCNK1, O00180; KCNK6, Q9Y257; KCNK7, Q9Y2U2                                                                     KCNK2, O95069; KCNK10, P57789; KCNK4, Q9NYG8                                                                                                                                          KCNK3, O14649; KCNK9, Q9NPC2; KCNK15, Q9H427                                                                                                               KCNK16, Q96T55; KCNK5, O95279; KCNK17, Q96T54                                                                                 KCNK13, Q9HB14; KCNK12, Q9HB15   KCNK18, Q7Z418
  Endogenous activators (EC~50~)   --                                                                                                              arachidonic acid                                                                                                                                                                      --                                                                                                                                                         --                                                                                                                            --                               --
  Activators (EC~50~)              --                                                                                                              halothane, riluzole                                                                                                                                                                   halothane                                                                                                                                                  --                                                                                                                            --                               --
  Inhibitors                       --                                                                                                              --                                                                                                                                                                                    anandamide, ruthenium red                                                                                                                                  --                                                                                                                            halothane                        --
  Endogenous inhibitors            --                                                                                                              --                                                                                                                                                                                    --                                                                                                                                                         --                                                                                                                            --                               arachidonic acid
  Functional characteristics       Background current                                                                                              Background current                                                                                                                                                                    Background current                                                                                                                                         Background current                                                                                                            Background current               Background current
  Comment                          K~2P~1.1 is inhibited by acid pH~i~, K~2P~6.1 is inhibited by acid pH~i~, K~2P~7.1 is inhibited by acid pH~i~   K~2P~2.1 is also activated by stretch, heat and acid pH~i~, K~2P~10.1 is also activated by stretch, heat and acid pH~i~, K~2P~4.1 is also activated by stretch, heat and acid pH~i~   K~2P~3.1 is also activated by alkakine pH~o~ and inhibited by acid pH~o~, K~2P~9.1 is also inhibited by acid pH~o~, K~2P~15.1 is inhibited by acid pH~o~   K~2P~16.1 is activated by alkaline pH~o~, K~2P~5.1 is activated by alkaline pH~o~, K~2P~17.1 is activated by alkaline pH~o~   --                               --
  -------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------------------- --------------------

Comments
--------

The K~2P~7.1, K~2P~15.1 and K~2P~12.1 subtypes, when expressed in isolation, are nonfunctional. All 4TM channels are insensitive to the classical potassium channel blockers tetraethylammonium and 4-aminopyridine, but are blocked to varying degrees by Ba^2+^ ions.

Voltage-gated and calcium-activated potassium channels
======================================================

Overview
--------

The 6TM family of K channels comprises the voltage-gated K~V~ subfamilies, the KCNQ subfamily the EAG subfamily (which includes herg channels), the Ca^2+^-activated Slo subfamily (actually with 7TM) and the Ca^2+^-activated SK subfamily. As for the 2TM family, the pore-forming a subunits form tetramers and heteromeric channels may be formed within subfamilies (*e.g*. K~V~1.1 with K~V~1.2; KCNQ2 with KCNQ3).

Subunits
--------

  ---------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------------ --------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------- ------------------------------------------------------------
  Nomenclature                 Kv1.1, Kv1.2, Kv1.3, Kv1.4, Kv1.5, Kv1.6, Kv1.7, Kv1.8                                                                     Kv2.1, Kv2.2                                           Kv3.1, Kv3.2, Kv3.3, Kv3.4                                                     Kv4.1, Kv4.2, Kv4.3                           Kv7.1, Kv7.2, Kv7.3, Kv7.4, Kv7.5                                           Kv10.1, Kv10.2, Kv11.1, Kv11.2, Kv11.3, Kv12.1, Kv12.2, Kv12.3                                                           KCa1.1, KCa4.1, KCa4.2, KCa5.1                                KCa2.1, KCa2.2, KCa2.3, KCa3.1
  HGNC, UniProt                KCNA1, Q09470; KCNA2, P16389; KCNA3, P22001; KCNA4, P22459; KCNA5, P22460; KCNA6, P17658; KCNA7, Q96RP8; KCNA10, Q16322    KCNB1, Q14721; KCNB2, Q92953                           KCNC1, P48547; KCNC2, Q96PR1; KCNC3, Q14003; KCNC4, Q03721                     KCND1, Q9NSA2; KCND2, Q9NZV8; KCND3, Q9UK17   KCNQ1, P51787; KCNQ2, O43526; KCNQ3, O43525; KCNQ4, P56696; KCNQ5, Q9NR82   KCNH1, O95259; KCNH5, Q8NCM2; KCNH2, Q12809; KCNH6, Q9H252; KCNH7, Q9NS40; KCNH8, Q96L42; KCNH3, Q9ULD8; KCNH4, Q9UQ05   KCNMA1, Q12791; KCNT1, Q5JUK3; KCNT2, Q6UVM3; KCNU1, A8MYU2   KCNN1, Q92952; KCNN2, Q9H2S1; KCNN3, Q9UGI6; KCNN4, O15554
  Associated subunits          K~v~ β1 and K~v~ β2                                                                                                        K~v~5.1, K~v~6.1--6.4, K~v~8.1--8.2 and K~v~9.1--9.3   MiRP2 is an associated subunit for K~v~3.4                                     KChIP and KChAP                               minK and MiRP2                                                              minK and MiRP1                                                                                                           --                                                            --
  Activators (EC~50~)          --                                                                                                                         --                                                     --                                                                             --                                            retigabine                                                                  --                                                                                                                       NS004, NS1619                                                 --
  Inhibitors                   α-dendrotoxin, margatoxin, noxiustoxin, tetraethylammonium (potent)tetraethylammonium (moderate)4-aminopyridine (potent)   tetraethylammonium (moderate)                          4-aminopyridine (potent), tetraethylammonium (potent)sea anemone toxin BDS-I   --                                            linopirdine, tetraethylammonium, XE991                                      astemizole, E4031, terfenadine                                                                                           charybdotoxin, iberiotoxin, tetraethylammonium                apamin, charybdotoxin
  Functional characteristics   K~V~, K~A~                                                                                                                 K~V~                                                   K~V~, K~A~                                                                     K~A~                                          cardiac IK~5~, M current, M current                                         cardiac IK~R~                                                                                                            Maxi K~Ca~ K~Na~ (slack & slick)                              SK~Ca~, IK~Ca~
  ---------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------------ --------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------- ------------------------------------------------------------

Ryanodine receptor
==================

Overview
--------

The ryanodine receptors (RyRs, provisional nomenclature) are found on intracellular Ca^2+^ storage/release organelles. The family of RyR genes encodes three highly related Ca^2+^ release channels: RyR1, RyR2 and RyR3, which assemble as large tetrameric structures. These RyR channels are ubiquitously expressed in many types of cells and participate in a variety of important Ca^2+^ signaling phenomena (neurotransmission, secretion, *etc*.). In addition to the three mammalian isoforms described below, various nonmammalian isoforms of the ryanodine receptor have been identified [@b218]. The function of the ryanodine receptor channels may also be influenced by closely associated proteins such as the tacrolimus (FK506)-binding protein, calmodulin [@b219], triadin, calsequestrin, junctin and sorcin, and by protein kinases and phosphatases.

Subunits
========

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      RyR1                                                                                                                                                                                                    RyR2                                                                                                                    RyR3
  HGNC, UniProt                     RYR1, P21817                                                                                                                                                                                            RYR2, Q92736                                                                                                            RYR3, Q15413
  Endogenous activators (EC~50~)    cytosolic ATP (endogenous; mM range), luminal Ca2+ (endogenous), cytosolic Ca2+ (endogenous; μM range)                                                                                                  cytosolic ATP (endogenous; mM range), luminal Ca2+ (endogenous), cytosolic Ca2+ (endogenous; μM range)                  cytosolic ATP (endogenous; mM range), cytosolic Ca2+ (endogenous; μM range)
  Activators (EC~50~)               caffeine (pharmacological; mM range), ryanodine (pharmacological; nM - μM range), suramin (pharmacological; μM range)                                                                                   caffeine (pharmacological; mM range), ryanodine (pharmacological; nM - μM range), suramin (pharmacological; μM range)   caffeine (pharmacological; mM range), ryanodine (pharmacological; nM - μM range)
  Endogenous antagonists (IC~50~)   cytosolic Mg2+ (mM range), cytosolic Ca2+ (Concentration range = \> 1x10^-4^ M)                                                                                                                         cytosolic Mg2+ (mM range), cytosolic Ca2+ (Concentration range = \> 1x10^-3^ M)                                         cytosolic Mg2+ (mM range), cytosolic Ca2+ (Concentration range = \> 1x10^-3^ M)
  Antagonists (IC~50~)              dantrolene                                                                                                                                                                                              --                                                                                                                      dantrolene
  Channel Blockers (IC~50~)         procaine, ruthenium red, ryanodine (Concentration range = \> 1x10^-4^ M)                                                                                                                                procaine, ruthenium red, ryanodine (Concentration range = \> 1x10^-4^ M)                                                ruthenium red
  Functional characteristics        Ca^2+^: (*P* ~Ca~/*P* ~K~∼6) single-channel conductance: ∼90 pS (50mM Ca^2+^), 770 pS (200 mM K^+^)                                                                                                     Ca^2+^: (*P* ~Ca~/*P* ~K~∼6) single-channel conductance: ∼90 pS (50mM Ca^2+^), 720 pS (210 mM K^+^)                     Ca^2+^: (*P* ~Ca~/*P*~K~∼6) single-channel conductance: ∼140 pS (50mM Ca^2+^), 777 pS (250 mM K^+^)
  Comment                           RyR1 is also activated by depolarisation *via* DHP receptor, calmodulin at low cytosolic Ca^2+^ concentrations, CaM kinase and PKA; antagonised by calmodulin at high cytosolic Ca^2+^ concentrations   RyR2 is also activated by CaM kinase and PKA; antagonised by calmodulin at high cytosolic Ca^2+^ concentrations         RyR3 is also activated by calmodulin at low cytosolic Ca^2+^ concentrations; antagonised by calmodulin at high cytosolic Ca^2+^ concentrations
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

The modulators of channel function included in this table are those most commonly used to identify ryanodine-sensitive Ca^2+^ release pathways. Numerous other modulators of ryanodine receptor/channel function can be found in the reviews listed below. The absence of a modulator of a particular isoform of receptor indicates that the action of that modulator has not been determined, not that it is without effect. The potential role of cyclic ADP ribose as an endogenous regulator of ryanodine receptor channels is controversial. A region of RyR likely to be involved in ion translocation and selection has been identified [@b217],[@b220].

Sodium leak channel, non-selective
==================================

Overview
--------

The sodium leak channel, non selective (NC-IUPHAR tentatively recommends the nomenclature Na~Vi~2.1) is structurally a member of the family of voltage-gated sodium channel family (Na~v~1.1 -- Na~v~1.9) [@b221],[@b228]. In contrast to the latter, Na~Vi~2.1, is voltage-insensitive (denoted in the subscript 'vi' in the tentative nomenclature) and possesses distinctive ion selectivity and pharmacological properties. Na~Vi~2.1, which is insensitive to tetrodotoxin (10 μM), has been proposed to mediate the tetrodotoxin-resistant and voltage-insensitive Na^+^ leak current (I~L~-Na) observed in many types of neurone [@b222]. However, whether Na~Vi~2.1 is constitutively active has been challenged [@b226]. Na~Vi~2.1 is widely distributed within the central nervous system and is also expressed in the heart and pancreas specifically, in rodents, within the islets of Langerhans [@b221],[@b222].

Subunits
========

  -------------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Activators                                                                                                                                                                                                                                                               Channel Blockers (IC50)                                                                   Functional characteristics
  Navi2.1        NALCN, Q8IZF0   Constitutively active (Lu *et al*., 2007), or activated downstream of Src family tyrosine kinases (SFKs) (Lu *et al*., 2009; Swayne *et al*., 2009); positively modulated by decreased extracellular Ca^2+^ concentration (Lu *et al*., 2010) [@b222]--[@b224],[@b226]   Gd3+ (1.4x10^-6^ M), Cd2+ (1.5x10^-4^ M), Co2+ (2.6x10^-4^ M), verapamil (3.8x10^-4^ M)   γ = 27 pS (by fluctuation analysis), *P*~Na~/*P*~Cs~ = 1.3, *P*~K~/*P*~Cs~ = 1.2, *P*~Ca~/*P*~Cs~ = 0.5, linear current voltage-relationship, voltage-independent and non-inactivating
  -------------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

In native and recombinant expression systems Na~Vi~2.1 can be activated by stimulation of NK~1~ (in hippocampal neurones), neurotensin (in ventral tegmental area neurones) and M3 muscarinic acetylcholine receptors (in MIN6 pancreatic β-cells) and in a manner that is independent of signalling through G-proteins [@b223],[@b226]. Pharmacological and molecular biological evidence indicates such modulation to occur though a pathway that involves the activation of Src family tyrosine kinases. It is suggested that Na~Vi~2.1 exists as a macromolecular complex with M3 receptors [@b226] and peptide receptors [@b223], in the latter instance in association with the protein UNC-80, which recruits Src to the channel complex [@b223],[@b227]. By contrast, stimulation of Na~vi~2.1 by decreased extracellular Ca^2+^ concentration is G-protein dependent and involves a Ca^2+^-sensing G protein-coupled receptor and UNC80 which links Na~vi~2.1 to the protein UNC79 in the same complex [@b224]. Na~Vi~2.1 null mutant mice have severe disturbances in respiratory rhythm and die within 24 hours of birth [@b222]. Na~vi~2.1 heterozygous knockout mice display increased serum sodium concentrations in comparison to wildtype littermates and a role for the channel in osmoregulation has been postulated [@b225].

Transient receptor potential channels
=====================================

Overview
--------

The TRP superfamily of channels (nomenclature agreed by NC-IUPHAR; [@b244],[@b351]), whose founder member is the *Drosophila* Trp channel, exists in mammals as six families; TRPC, TRPM, TRPV, TRPA, TRPP and TRPML based on amino acid homologies. TRP subunits contain six putative transmembrane domains and assemble as homo- or hetero-tetramers to form cation selective channels with diverse modes of activation and varied permeation properties (reviewed by [@b314]). Established, or potential, physiological functions of the individual members of the TRP families are discussed in detail in the recommended reviews and a compilation edited by Islam [@b271]. The established, or potential, involvement of TRP channels in disease is reviewed in [@b279],[@b307] and [@b308], together with a special edition of *Biochemica et Biophysica Acta* on the subject [@b307]. The pharmacology of most TRP channels is poorly developed [@b351]. Broad spectrum agents are listed in the tables along with more selective, or recently recognised, ligands that are flagged by the inclusion of a primary reference. Most TRP channels are regulated by phosphoinostides such as PtIns(4,5)P~2~ and IP3 although the effects reported are often complex, occasionally contradictory, and likely be dependent upon experimental conditions (reviewed by [@b309],[@b327],[@b343]). Such regulation is generally not included in the tables.

### TRPA (ankyrin) family 

TRPA1 is the sole mammalian member of this group (reviewed by [@b259]). In some [@b234],[@b274],[@b330],[@b334], but not other [@b272],[@b303], studies TRPA1 is activated by noxious cold. One study suggests that activation of TRPA1 is secondary to a cold-induced elevation of \[Ca^2+^\]~i~ [@b357], but this has been refuted [@b274]. Additionally, TRPA1 has been proposed to be a component of a mechanosensitive transduction channel of vertebrate hair cells [@b246],[@b303], but TRPA1^(-/-)^ mice demonstrate no impairment in hearing, or vestibular function [@b238],[@b284]. There is consensus that TRPA1 acts as a nociceptor for environmental irritants [@b235].

### TRPC (canonical) family 

Members of the TRPC subfamily (reviewed by [@b229],[@b230],[@b241],[@b242],[@b258],[@b277],[@b316],[@b324]) fall into the subgroups outlined below. TRPC2 (not tabulated) is a pseudogene in man. It is generally accepted that all TRPC channels are activated downstream of G~q/11~-coupled receptors, or receptor tyrosine kinases (reviewed by [@b321],[@b337],[@b351]). A comprehensive listing of G-protein coupled receptors that activate TRPC channels is given in [@b229]. Hetero-oligomeric complexes of TRPC channels and their association with proteins to form signalling complexes are detailed in [@b230] and [@b278]. TRPC channels have frequently been proposed to act as store-operated channels (SOCs) (or compenents of mulimeric complexes that form SOCs), activated by depletion of intracellular calcium stores (reviewed by [@b230],[@b243],[@b317],[@b322],[@b329],[@b354]), but this is controversial. All members of the TRPC family are blocked by 2-APB and SKF96356 [@b265],[@b266]. Activation of TRPC channels by lipids is discussed by [@b241].

### TRPC1/C4/C5 subgroup 

TRPC4/C5 may be distinguished from other TRP channels by their potentiation by micromolar concentrations of La^3+^.

### TRPC3/C6/C7 subgroup 

All members are activated by diacylglycerol independent of protein kinase C stimulation [@b266].

### TRPM (melastatin) family 

Members of the TRPM subfamily (reviewed by [@b257],[@b265],[@b317],[@b356]) fall into the five subgroups outlined below.

### TRPM1/M3 subgroup 

TRPM1 exists as five splice variants and is involved in normal melanocyte pigmentation [@b312] and is also a visual transduction channel in retinal ON bipolar cells [@b283]. TRPM3 (reviewed by [@b313]) exists as multiple splice variants four of which (mTRPM3α1, mTRPM3α2, hTRPM3a and hTRPM3~1325~) have been characterised and found to differ significantly in their biophysical properties. TRPM3 has recently been found to contribute to the detection of noxious heat [@b346].

### TRPM2 

TRPM2 functions as a sensor of redox status in cells and is also activated by heat (reviewed by [@b353]). Numerous splice variants of TRPM2 exist which differ in their activation mechanisms [@b254].

### TRPM4/5 subgroup 

TRPM4 and TRPM5 are thermosensitive and have the distinction within all TRP channels of being impermeable to Ca^2+^ [@b351]. A splice variant of TRPM4 (*i.e.*TRPM4b) and TRPM5 are molecular candidates for endogenous calcium-activated cation (CAN) channels [@b262]. TRPM4 has been shown to be an important regulator of Ca^2+^ entry in to mast cells [@b339] and dendritic cell migration [@b236]. TRPM5 in taste receptor cells of the tongue appears essential for the transduction of sweet, amino acid and bitter stimuli [@b289].

### TRPM6/7 subgroup 

TRPM6 and 7 combine channel and enzymatic activities ('chanzymes') and are involved in Mg^2+^ homeostasis (reviewed by [@b237],[@b318],[@b328]).

### TRPM8 

Is a channel activated by cooling and pharmacological agents evoking a 'cool' sensation and participates in the thermosensation of cold temperatures [@b240],[@b245],[@b252] reviewed by [@b282],[@b291],[@b302],[@b344].

### TRPML (mucolipin) family 

The TRPML family [@b323],[@b325],[@b355] consists of three mammalian members (TRPML1-3). TRPML channels are probably restricted to intracellular vesicles and mutations in the gene (*MCOLN1*) encoding TRPML1 (mucolipin-1) are the cause of the neurodegenerative disorder mucolipidosis type IV (MLIV) in man. TRPML1 is a cation selective ion channel that is important for sorting/transport of endosomes in the late endocytotic pathway and specifically fusion between late endosome-lysosome hybrid vesicles. TRPML2 (MCLN2) remains to be functionally characterised in detail. TRPML3 is important for hair cell maturation, stereocilia maturation and intracellular vesicle transport. A naturally occurring gain of function mutation in TRPML3 (*i.e.* A419P) results in the varitint waddler (V*a*) mouse phenotype (reviewed by [@b310],[@b325]).

### TRPP (polycystin) family 

The TRPP family (reviewed by [@b249],[@b251],[@b260],[@b268],[@b349]) subsumes the polycystins that are divided into two structurally distinct groups, polycystic kidney disease 1-like (PKD1-like) and polycystic kidney disease 2-like (PKD2-like). Members of the PKD1-like group, in mammals, include PKD1 (reclassified as TRPP1), PDKREJ, PKD1L1, PKD1L2 and PKD1L3. The PKD2-like members comprise PKD2, PKD2L1 and PKD2L2, which have renamed TRPP2, TRPP3 and TRPP5, respectively [@b300]. PKDREJ (Q9NTG1), PKD1L1 (Q8TDX9), mouse PKD1L2 (Q7TN88), PKD1L3 (Q7Z443) and TRPP5 (PKD2L2, Q9NZM6) are not listed in the table due to lack of functional data. Similarly, TRPP1 (P98161) is also omitted because although one study [@b233] has reported the induction of a cation conductance in CHO cells transfected with TRPP1, there is no unequivocal evidence that TRPP1 is a channel *per se* and in other studies (*e.g.* [@b250],[@b264]) TRPP1 is incapable of producing currents.

### TRPV (vanilloid) family 

Members of the TRPV family (reviewed by [@b340]) can broadly be divided into the theromosensitive, non-selective cation channels, TRPV1-4 and the calcium selective channels TRPV5 and TRPV6.

### TRPV1-V4 subfamily 

TRPV1 is involved in the development of thermal hyperalgesia following inflammation and may contribute to the detection of noxius heat (reviewed by [@b320],[@b333],[@b335]). Numerous splice variants of TRPV1 have been described, some of which modulate the activity of TRPV1, or act in a dominant negative manner when co-expressed with TRPV1 [@b331]. The pharmacology of TRPV1 channels is discussed in detail in [@b263] and [@b345]. TRPV2 is probably not a thermosensor in man [@b315], but has recently been implicated in innate immunity [@b290]. TRPV3 and TRPV4 are both thermosensitive, with the latter also having a mechanosensing function [@b255].

### TRPV5/V6 subfamily 

Under physiological conditions, TRPV5 and TRPV6 are calcium selective channels involved in the absorption and reabsorption of calcium across intestinal and kidney tubule epithelia (reviewed by [@b248],[@b348]).

Subunits
========

  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     TRPC1                                                                                                                                                                                                                   TRPC4                                                                                                                                     TRPC5
  HGNC, UniProt                    TRPC1, P48995                                                                                                                                                                                                           TRPC4, Q9UBN4                                                                                                                             TRPC5, Q9UL62
  Chemical activators              NO-mediated cysteine S-nitrosylation                                                                                                                                                                                    --                                                                                                                                        --
  Physical activators              membrane stretch (likely direct)                                                                                                                                                                                        --                                                                                                                                        --
  Other chemical activators        --                                                                                                                                                                                                                      NO-mediated cysteine S-nitrosylation, potentiation by extracellular protons                                                               NO-mediated cysteine S-nitrosylation (disputed), potentiation by extracellular protons
  Physical activators              --                                                                                                                                                                                                                      --                                                                                                                                        membrane stretch (likely indirect)
  Endogenous activators (EC~50~)   --                                                                                                                                                                                                                      --                                                                                                                                        lysophosphatidylcholine, intracellular Ca2+ (at negative potentials) (6.35x10^-7^ M)
  Activators (EC~50~)              --                                                                                                                                                                                                                      La3+ (μM range)                                                                                                                           7,4\'-dihydroxyisoflavone, genistein (independent of tyrosine kinase inhibition) [@b350], La3+ (μM range), Gd3+ (Concentration range = 1x10^-4^ M), Pb2+ (Concentration range = 5x10^-6^ M)
  Channel Blockers (IC~50~)        2-APB, Gd3+, GsMTx-4, La3+, SKF96365                                                                                                                                                                                    2-APB, La3+ (mM range), niflumic acid, SKF96365, ML204 (2.9x10^-6^ M) [@b299]                                                             2-APB, BTP2, chlorpromazine, flufenamic acid, GsMTx-4, KB-R7943, La3+ (mM range), SKF96365, ML204 (∼1x10^-5^ M) [@b299]
  Functional characteristics       γ = 16 pS (fluctuation analysis), conducts mono- and di-valent cations non-selectively; monovalent cation current suppressed by extracellular Ca^2+^; non-rectifying, or mildly inwardly rectifying; non-inactivating   γ = 30 --41 pS, conducts mono and di-valent cations non-selectively (P~Ca~/P~Na~ = 1.1 -- 7.7); dual (inward and outward) rectification   γ = 41-63 pS; conducts mono-and di-valent cations non-selectively (P~Ca~/P~Na~ = 1.8 -- 9.5); dual rectification (inward and outward) as a homomer, outwardly rectifying when expressed with TRPC1 or TRPC4
  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     TRPC3                                                                                                                                                                                       TRPC6                                                                                                                                                                                                                                                  TRPC7
  HGNC, UniProt                    TRPC3, Q13507                                                                                                                                                                               TRPC6, Q9Y210                                                                                                                                                                                                                                          TRPC7, Q9HCX4
  Chemical activators              diacylglycerols                                                                                                                                                                             --                                                                                                                                                                                                                                                     diacylglycerols
  Other chemical activators        --                                                                                                                                                                                          diacylglycerols                                                                                                                                                                                                                                        --
  Physical activators              --                                                                                                                                                                                          membrane stretch (likely indirect)                                                                                                                                                                                                                     --
  Endogenous activators (EC~50~)   --                                                                                                                                                                                          20-HETE, arachidonic acid, lysophosphatidylcholine                                                                                                                                                                                                     --
  Activators (EC~50~)              --                                                                                                                                                                                          2,4 diahexanxoylphloroglucinol [@b287], flufenamate, hyperforin [@b288]                                                                                                                                                                                --
  Channel Blockers (IC~50~)        2-APB, ACAA, BTP2, Gd3+, KB-R7943, La3+, Ni2+, Pyr3 [@b280], SKF96365                                                                                                                       2-APB, ACAA, amiloride, Cd2+, Gd3+, GsMTx-4, Extracellular H+, KB-R7943, ML9, SKF96365, La3+ (∼6x10^-6^ M)                                                                                                                                             2-APB, amiloride, La3+, SKF96365
  Functional characteristics       γ = 66 pS; conducts mono and di-valent cations non-selectively (P~Ca~/P~Na~ = 1.6); monovalent cation current suppressed by extracellular Ca^2+^; dual (inward and outward) rectification   γ = 28-37 pS; conducts mono and divalent cations with a preference for divalents (P~Ca~/P~Na~ = 4.5--5.0); monovalent cation current suppressed by extracellular Ca^2+^ and Mg^2+^, dual rectification (inward and outward), or inward rectification   γ = 25--75 pS; conducts mono and divalent cations with a preference for divalents (P~Ca~/ P~Cs~ = 5.9); modest outward rectification (monovalent cation current recorded in the absence of extracellular divalents); monovalent cation current suppressed by extracellular Ca^2+^ and Mg^2+^
  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                           TRPM1                                                                                           TRPM3
  HGNC, UniProt                          TRPM1, Q7Z4N2                                                                                   TRPM3, Q9HCF6
  Physical activators                    --                                                                                              heat (Q~10~ = 7.2 between 15 - 25°C; Vriens *et al*., 2011), hypotonic cell swelling [@b346]
  Endogenous activators (EC~50~)         pregnenolone sulphate [@b285]                                                                   epipregnanolone sulphate [@b294], pregnenolone sulphate [@b347]
  Activators (EC~50~)                    --                                                                                              dihydro-D-erythrosphingosine, nifedipine, sphingosine
  Endogenous channel blockers (IC~50~)   Zn2+ (1x10^-6^ M)                                                                               intracellular Mg2+, extracellular Na+ (TRPM3α2 only)
  Channel Blockers (IC~50~)              --                                                                                              2-APB, Gd3+, La3+, mefenamic acid [@b281], pioglitazone (independent of PPAR-γ) [@b295], rosiglitazone, troglitazone
  Functional characteristics             Conducts mono- and di-valent cations non-selectively, dual rectification (inward and outward)   TRPM3~1235~: γ = 83 pS (Na^+^ current), 65 pS (Ca^2+^ current); conducts mono and di-valent cations non-selectively (P~Ca~/P~Na~ = 1.6) TRPM3α1: selective for monovalent cations (P~Ca~/P~Cs~∼0.1); TRPM3α2: conducts mono- and di-valent cations non-selectively (P~Ca~/P~Cs~ = 1--10); Outwardly rectifying (magnitude varies between spice variants)
  -------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------- --------------- --------------------------------------------------------------------------------------- --------------------- ----------------------------------------------------------------------------------------------------------------------------- --------------------- -------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Other chemical activators                                                               Physical activators   Endogenous activators (EC~50~)                                                                                                Activators (EC~50~)   Endogenous channel blockers (IC~50~)   Channel Blockers (IC~50~)                                           Functional characteristics
  TRPM2          TRPM2, O94759   agents producing reactive oxygen (e.g. H~2~O~2~) and nitrogen (e.g. GEA 3162) species   heat ∼ 35°C           intracellular ADP ribose, arachidonic acid (Potentiation), intracellular cADPR, intracellular Ca2+ (*via* calmodulin), H2O2   GEA 3162              extracellular H+, Zn2+ (1x10^-6^ M)    2-APB, ACAA, clotrimazole, econazole, flufenamic acid, miconazole   γ = 52-60 pS at negative potentials, 76 pS at positive potentials; conducts mono- and di-valent cations non-selectively (P~Ca~/P~Na~ = 0.6--0.7); non-rectifying; inactivation at negative potentials; activated by oxidative stress probably *via* PARP-1, PARP inhibitors reduce activation by oxidative stress, activation inhibited by suppression of APDR formation by glycohydrolase inhibitors
  -------------- --------------- --------------------------------------------------------------------------------------- --------------------- ----------------------------------------------------------------------------------------------------------------------------- --------------------- -------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     TRPM4                                                                                                                                                                                                                                                      TRPM5
  HGNC, UniProt                    TRPM4, Q8TD43                                                                                                                                                                                                                                              TRPM5, Q9NZQ8
  Other channel blockers           intracellular nucleotides including ATP, ADP, AMP and AMP-PNP with an IC~50~ range of 1.3--1.9 μM                                                                                                                                                          --
  Physical activators              membrane depolarization (V~½~ = -20 mV to + 60 mV dependent upon conditions) in the presence of elevated \[Ca^2+^\]~i~, heat (Q~10~ = 8.5 @ +25 mV between 15 and 25°C)                                                                                    membrane depolarization (V~½~ = 0 to + 120 mV dependent upon conditions), heat (Q~10~ = 10.3 @ -75 mV between 15 and 25°C)
  Endogenous activators (EC~50~)   intracellular Ca2+ (transient activation of whole cell current) (3x10^-7^ -- 2x10^-5^ M)                                                                                                                                                                   intracellular Ca2+ (transient activation) (6.35x10^-7^ -- 8.4x10^-7^ M)
  Activators (EC~50~)              BTP2 (Potentiation), decavanadate                                                                                                                                                                                                                          rosiglitazone [@b295]
  Channel Blockers (IC~50~)        9-phenanthrol, clotrimazole, flufenamic acid (2.8x10^-6^ M), intracellular spermine (3.5x10^-5^ -- 6.1x10^-5^ M), adenosine (6.3x10^-4^ M)                                                                                                                 flufenamic acid (2.4x10^-5^ M), intracellular spermine (3.7x10^-5^ M), Extracellular H+ (6.3x10^-4^ M)
  Functional characteristics       γ = 23 pS (within the range 60 to +60 mV); permeable to monovalent cations; impermeable to Ca^2+^; strong outward rectification; slow activation at positive potentials, rapid deactivation at negative potentials, deactivation blocked by decavanadate   γ = 15-25 pS; conducts monovalent cations selectively (P~Ca~/P~Na~ = 0.05); strong outward rectification; slow activation at positive potentials, rapid inactivation at negative potentials; activated and subsequently desensitized by \[Ca^2+^\]~I~
  Comment                          --                                                                                                                                                                                                                                                         TRPM5 is not blocked by ATP
  -------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                           TRPM6                                                                                                                                                                                                                                                                                                                                                                      TRPM7
  HGNC, UniProt                          TRPM6, Q9BX84                                                                                                                                                                                                                                                                                                                                                              TRPM7, Q96QT4
  Other chemical activators              constitutively active, activated by reduction of intracellular Mg^2+^                                                                                                                                                                                                                                                                                                      activation of PKA
  Endogenous activators (EC~50~)         extracellular H+ (Potentiation, μM range), intracellular Mg2+                                                                                                                                                                                                                                                                                                              intracellular ATP (Potentiation), cAMP (elevated cAMP levels), Extracellular H+ (Potentiation)
  Activators (EC~50~)                    2-APB (Potentiation)                                                                                                                                                                                                                                                                                                                                                       2-APB (mM range)
  Endogenous channel blockers (IC~50~)   Mg2+ (inward current mediated by monovalent cations is blocked) (1.1x10^-6^ -- 3.4x10^-6^ M), Ca2+ (inward current mediated by monovalent cations is blocked) (4.8x10^-6^ -- 5.4x10^-6^ M)                                                                                                                                                                                 Mg2+
  Channel Blockers (IC~50~)              ruthenium red (1x10^-7^ M) \[*voltage dependent* -120.0 mV\]                                                                                                                                                                                                                                                                                                               2-APB (μM range), carvacrol, La3+, spermine (permeant blocker)
  Functional characteristics             γ = 40--87 pS; permeable to mono- and di-valent cations with a preference for divalents (Mg^2+^ \> Ca^2+^; P~Ca~/P~Na~ = 6.9), conductance sequence Zn^2+^ \> Ba^2+^ \> Mg^2+^ = Ca^2+^ = Mn^2+^ \> Sr^2+^ \> Cd^2+^\> Ni^2+^; strong outward rectification abolished by removal of extracellular divalents, inhibited by intracellular Mg^2+^ (IC~50~ = 0.5 mM) and ATP   γ = 40-105 pS at negative and positive potentials respectively; conducts mono-and di-valent cations with a preference for monovalents (P~Ca~/P~Na~ = 0.34); conductance sequence Ni^2+^ \> Zn^2+^ \> Ba^2+^ = Mg^2+^ \> Ca^2+^ = Mn^2+^ \> Sr^2+^ \> Cd^2+^; outward rectification, decreased by removal of extracellular divalent cations; inhibited by intracellular Mg^2+^, Ba^2+^, Sr^2+^, Zn^2+^, Mn^2+^ and Mg.ATP (disputed); activated by and intracellular alkalinization; sensitive to osmotic gradients
  -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------- --------------- ------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Other chemical activators                                                 Physical activators                                             Activators (EC~50~)                                                                                                                       Channel Blockers (IC~50~)                                                                                                                                        Functional characteristics                                                                                                                                                                                                                                                                                       Comment
  TRPM8          TRPM8, Q7Z2W7   agonist activities are temperature dependent and potentiated by cooling   depolarization (V~½~ ∼ +50 mV at 15°C), cooling (\< 22--26°C)   icilin (requires intracellular Ca^2+^ as a co-factor for full agonist activity), (-)-menthol (inhibited by intracellular Ca^2+^), WS-12   2-APB, 5-benzyloxytryptamine, ACAA, AMTB [@b286], anandamide, BCTC, cannabidiol, capsazepine, clotrimazole, Δ9-tetrahydrocannabinol, La3+, linoleic acid, NADA   γ = 40-83 pS at positive potentials; conducts mono- and di-valent cations non-selectively (P~Ca~/P~Na~ = 1.0--3.3); pronounced outward rectification; demonstrates densensitization to chemical agonists and adaptation to a cold stimulus in the presence of Ca^2+^; modulated by lysophospholipids and PUFAs   cannabidiol and Δ9-tetrahydrocannabinol are examples of cannabinoids. TRPM8 is insensitive to ruthenium red
  -------------- --------------- ------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------

Comments
========

Ca^2+^ activates all splice variants of TRPM2, but other activators listed are effective only at the full length isoform [@b254]. Inhibition of TRPM2 by clotrimazole, miconazole, econazole, flufenamic acid is largely irreversible. TRPM4 exists as multiple spice variants: data listed are for TRPM4b. The sensitivity of TRPM4b and TRPM5 to activation by \[Ca^2+^\]~i~ demonstrates a pronounced and time-dependent reduction following excision of inside-out membrane patches [@b338]. The V~½~ for activation of TRPM4 and TRPM5 demonstrates a pronounced negative shift with increasing temperature. Activation of TRPM8 by depolarization is strongly temperature-dependent via a channel-closing rate that decreases with decreasing temperature. The V~½~ is shifted in the hyperpolarizing direction both by decreasing temperature and by exogenous agonists, such as (-)-menthol [@b342] whereas antagonists produce depolarizing shifts in V~½~ [@b301]. The V~½~ for the native channel is far more positive than that of heterologously expressed TRPM8 [@b301]. It should be noted that (-)-menthol and structurally related compounds can elicit release of Ca^2+^ from the endoplasmic reticulum independent of activation of TRPM8 [@b293]. Intracellular pH modulates activation of TRPM8 by cold and icilin, but not (-)-menthol [@b231].

  -------------- --------------- -------------------------------------------------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Other chemical activators                                            Physical activators           Activators (EC~50~)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Channel Blockers (IC~50~)                                                                                                                       Functional characteristics
  TRPA1          TRPA1, O75762   isothiocyanates (covalent) and 1,4-dihydropyridines (non-covalent)   cooling (\<17°C) (disputed)   chlorobenzylidene malononitrile (Activation, covalent), cinnamaldehyde (Activation, covalent), formalin (Activation, covalent), icilin (Activation, non-covalent), (-)-menthol (Activation, non-covalent) (Concentration range = 1x10^-6^ - 1x10^-4^ M), thymol (Activation, non-covalent) (Concentration range = 1x10^-6^ - 1x10^-4^ M), acrolein (Agonist, covalent) (5.011x10^-6^ M) \[Physiological voltage\] [@b238], allicin (Agonist, covalent) (7.943x10^-6^ M) \[Physiological voltage\] [@b239], Δ9-tetrahydrocannabinol (Agonist, non-covalent) (1.259x10^-5^ M) \[-60.0 mV\] [@b272], nicotine (Activation, non-covalent) (∼2x10^-5^ M), URB597 (Agonist, non-covalent) (2.4x10^-5^ M) [@b306]   ruthenium red (Inhibition) (\<1x10^-6^ -- 3x10^-6^ M), AP18 (Inhibition) (3.1x10^-6^ M) [@b319], HC030031 (Inhibition) (6.2x10^-6^ M) [@b296]   γ = 87--100 pS; conducts mono- and di-valent cations non-selectively (P~Ca~/PN~a~ = 0.84); outward rectification; activated by elevated intracellular Ca^2+^
  -------------- --------------- -------------------------------------------------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Agents activating TRPA1 in a covalent manner are thiol reactive electrophiles that bind to cysteine and lysine residues within the cytoplasmic domain of the channel [@b267],[@b292]. TRPA1 is activated by a wide range of endogenous and exogenous compounds and only a few representative examples are mentioned in the table: an exhaustive listing can be found in [@b235]. In addition, TRPA1 is potently activated by intracellular zinc (EC~50~ = 8 nM) [@b232],[@b269].

  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     TRPV1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       TRPV2                                                                                                                                                                                                                                                                                                                             TRPV3                                                                                                                                                                    TRPV4
  HGNC, UniProt                    TRPV1, Q8NER1                                                                                                                                                                                                                                                                                                                                                                                                                                                                               TRPV2, Q9Y5S1                                                                                                                                                                                                                                                                                                                     TRPV3, Q8NET8                                                                                                                                                            TRPV4, Q9HBA0
  Other chemical activators        NO-mediated cysteine S-nitrosylation                                                                                                                                                                                                                                                                                                                                                                                                                                                        --                                                                                                                                                                                                                                                                                                                                NO-mediated cysteine S-nitrosylation                                                                                                                                     epoxyeicosatrieonic acids and NO-mediated cysteine S-nitrosylation
  Physical activators              depolarization (V~½~ ∼ 0 mV at 35°C), noxious heat (\> 43°C at pH 7.4)                                                                                                                                                                                                                                                                                                                                                                                                                      noxious heat (\> 35°C; rodent, not human) [@b305]                                                                                                                                                                                                                                                                                 depolarization (V~½~ ∼ +80 mV, reduced to more negative values following heat stimuli), heat (23°C - 39°C, temperature threshold reduces with repeated heat challenge)   constitutively active, heat (\> 24°C - 32°C), mechanical stimuli
  Endogenous activators (EC~50~)   12S-HPETE, 15S-HPETE, 5S-HETE, LTB4, Extracellular H+ (at 37°C) (3.98x10^-6^ M)                                                                                                                                                                                                                                                                                                                                                                                                             --                                                                                                                                                                                                                                                                                                                                --                                                                                                                                                                       --
  Activators (EC~50~)              camphor, capsaicin, diphenylboronic anhydride, DkTx (Irreversible agonist), olvanil, phenylacetylrinvanil, resiniferatoxin                                                                                                                                                                                                                                                                                                                                                                  Δ9-tetrahydrocannabinol, diphenylboronic anhydride, probenecid, 2-APB (1x10^-5^ M - Rat) [@b305],[@b326], cannabidiol (Activation) (3.17x10^-5^ M) [@b326]                                                                                                                                                                        2-APB, 6-tert-butyl-m-cresol, camphor, carvacrol, diphenylboronic anhydride, eugenol, incensole acetate, (-)-menthol, thymol                                             4α-PDD, 4α-PDH, bisandrographolide, phorbol 12-myristate 13-acetate, GSK1016790A (2.1x10^-9^ M) [@b336], RN1747 (7.7x10^-7^ M) [@b341]
  Selective activators (EC~50~)    --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          2-APB (Agonist) (Mouse) \[Physiological voltage\] [@b270],[@b273],[@b297],[@b298]                                                                                                                                                                                                                                                 --                                                                                                                                                                       --
  Channel Blockers (IC~50~)        2-APB, allicin, anandamide, NADA, SB452533, AMG517 (9x10^-10^ M), 5\'-iodoresiniferatoxin (3.9x10^-9^ M), AMG628 (3.7x10^-9^ M), SB705498 (3x10^-9^ -- 6x10^-9^ M), A425619 (5x10^-9^ M), A778317 (5x10^-9^ M), 6-iodo-nordihydrocapsaicin (1x10^-8^ M), JYL1421 (9.2x10^-9^ M), BCTC (6x10^-9^ -- 3.5x10^-8^ M), SB366791 (1.8x10^-8^ M), JNJ17203212 (6.5x10^-8^ M), capsazepine (4x10^-8^ -- 2.8x10^-7^ M), ruthenium red (9x10^-8^ -- 2.2x10^-7^ M)                                     amiloride, La3+, SKF96365, TRIM, ruthenium red (6x10^-7^ M)                                                                                                                                                                                                                                                                       diphenyltetrahydrofuran (Concentration range = 6x10^-6^ - 1x10^-5^ M), ruthenium red (Concentration range = \< 1x10^-6^ M)                                               Gd3+, La3+, ruthenium red \[*voltage dependent*\], HC067047 (1.7x10^-8^ M) [@b256], RN1734 (2.3x10^-6^ M) [@b341]
  Radioligands (*K*~d~)            \[125I\]resiniferatoxin, \[3H\]resiniferatoxin, \[3H\]A778317 (3.4x10^-9^ M)                                                                                                                                                                                                                                                                                                                                                                                                                --                                                                                                                                                                                                                                                                                                                                --                                                                                                                                                                       --
  Functional characteristics       γ = 35 pS at -- 60 mV; 77 pS at + 60 mV, conducts mono and di-valent cations with a selectivity for divalents (P~Ca~/P~Na~ = 9.6); voltage- and time- dependent outward rectification; potentiated by ethanol; activated/potentiated/upregulated by PKC stimulation; extracellular acidification facilitates activation by PKC; desensitisation inhibited by PKA; inhibited by Ca^2+^/ calmodulin; cooling reduces vanilloid-evoked currents; may be tonically active at body temperature   Conducts mono- and di-valent cations (P~Ca~/P~Na~ = 0.9--2.9); dual (inward and outward) rectification; current increases upon repetitive activation by heat; translocates to cell surface in response to IGF-1 to induce a constitutively active conductance, translocates to the cell surface in response to membrane stretch   γ = 197 pS at = +40 to +80 mV, 48 pS at negative potentials; conducts mono- and di-valent cations; outward rectification; potentiated by arachidonic acid                γ = ∼60 pS at --60 mV, ∼90-100 pS at +60 mV; conducts mono- and di-valent cations with a preference for divalents (P~Ca~/P~Na~ = 6--10); dual (inward and outward) rectification; potentiated by intracellular Ca^2+^ *via* Ca^2+^/ calmodulin; inhibited by elevated intracellular Ca^2+^ *via* an unknown mechanism (IC~50~ = 0.4 μM)
  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                 TRPV5                                                                                                                                                                                                                                                                                                                                                                                                                                                               TRPV6
  HGNC, UniProt                TRPV5, Q9NQA5                                                                                                                                                                                                                                                                                                                                                                                                                                                       TRPV6, Q9H1D0
  Activators                   constitutively active (with strong buffering of intracellular Ca^2+^)                                                                                                                                                                                                                                                                                                                                                                                               constitutively active (with strong buffering of intracellular Ca^2+^)
  Activators (EC~50~)          --                                                                                                                                                                                                                                                                                                                                                                                                                                                                  2-APB (Potentiation)
  Other channel blockers       Pb2+ = Cu2+ = Gd3+ \> Cd2+ \> Zn2+ \> La3+ \> Co2+ \> Fe2+                                                                                                                                                                                                                                                                                                                                                                                                          --
  Channel Blockers (IC~50~)    econazole, Mg2+, miconazole, ruthenium red (1.21x10^-7^ M)                                                                                                                                                                                                                                                                                                                                                                                                          Cd2+, La3+, Mg2+, ruthenium red (9x10^-6^ M)
  Functional characteristics   γ = 59--78 pS for monovalent ions at negative potentials, conducts mono- and di-valents with high selectivity for divalents (P~Ca~/P~Na~ \> 107); voltage- and time- dependent inward rectification; inhibited by intracellular Ca^2+^ promoting fast inactivation and slow downregulation; feedback inhibition by Ca^2+^ reduced by calcium binding protein 80-K-H; inhibited by extracellular and intracellular acidosis; upregulated by 1,25-dihydrovitamin D3   γ = 58--79 pS for monovalent ions at negative potentials, conducts mono- and di-valents with high selectivity for divalents (P~Ca~/P~Na~ \> 130); voltage- and time-dependent inward rectification; inhibited by intracellular Ca^2+^ promoting fast and slow inactivation; gated by voltage-dependent channel blockade by intracellular Mg^2+^; slow inactivation due to Ca^2+^-dependent calmodulin binding; phosphorylation by PKC inhibits Ca^2+^-calmodulin binding and slow inactivation; upregulated by 1,25-dihydroxyvitamin D3
  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Activation of TRPV1 by depolarisation is strongly temperature-dependent via a channel opening rate that increases with increasing temperature. The V~½~ is shifted in the hyperpolarizing direction both by increasing temperature and by exogenous agonists [@b342]. The sensitivity of TRPV4 to heat, but not 4α-PDD is lost upon patch excision. TRPV4 is activated by anandamide and arachidonic acid following P450 epoxygenase-dependent metabolism to 5,6-epoxyeicosatrienoic acid (reviewed by [@b311]). Activation of TRPV4 by cell swelling, but not heat, or phorbol esters, is mediated via the formation of epoxyeicosatrieonic acids. Phorbol esters bind directly to TRPV4. TRPV5 preferentially conducts Ca^2+^ under physiological conditions, but in the absence of extracellular Ca^2+^, conducts monovalent cations. Single channel conductances listed for TRPV5 and TRPV6 were determined in divalent cation-free extracellular solution. Ca^2+^-induced inactivation occurs at hyperpolarized potentials when Ca^2+^ is present extracellularly. Single channel events cannot be resolved (probably due to greatly reduced conductance) in the presence of extracellular divalent cations. Measurements of P~Ca~/P~Na~ for TRPV5 and TRPV6 are dependent upon ionic conditions due to anomalous mole fraction behaviour. Blockade of TRPV5 and TRPV6 by extracellular Mg^2+^ is voltage-dependent. Intracellular Mg^2+^ also exerts a voltage dependent block that is alleviated by hyperpolarization and contributes to the time-dependent activation and deactivation of TRPV6 mediated monovalent cation currents. TRPV5 and TRPV6 differ in their kinetics of Ca^2+^-dependent inactivation and recovery from inactivation. TRPV5 and TRPV6 function as homo- and hetero-tetramers.

  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                 TRPML1                                                                                                                                                                                                                                                                                                                                                                                           TRPML2                                                                                                                               TRPML3
  HGNC, UniProt                MCOLN1, Q9GZU1                                                                                                                                                                                                                                                                                                                                                                                   MCOLN2, Q8IZK6                                                                                                                       MCOLN3, Q8TDD5
  Activators                   TRPML1^Va^: Constitutively active, current potentiated by extracellular acidification (equivalent to intralysosomal acidification)                                                                                                                                                                                                                                                               TRPML2^Va^: Constitutively active, current potentiated by extracellular acidification (equivalent to intralysosomal acidification)   TRPML3^Va^: Constitutively active, current inhibited by extracellular acidification (equivalent to intralysosomal acidicification), Wild type TRPML3: Activated by Na^+^-free extracellular (extracytosolic) solution and membrane depolarization, current inhibited by extracellular acidification (equivalent to intralysosomal acidicification)
  Channel Blockers (IC~50~)    --                                                                                                                                                                                                                                                                                                                                                                                               --                                                                                                                                   Gd3+
  Functional characteristics   TRPML1^Va^: γ = 40 pS and 76-86 pS at very negative holding potentials with Fe^2+^ and monovalent cations as charge carriers, respectively; conducts Na^+^≅ K^+^\>Cs^+^ and divalent cations (Ba^2+^\>Mn2^+^\>Fe^2+^\>Ca^2+^\> Mg^2+^\> Ni^2+^\>Co^2+^\> Cd^2+^\>Zn^2+^\>\>Cu^2+^) protons; monovalent cation flux suppressed by divalent cations (*e.g.* Ca^2+^, Fe^2+^); inwardly rectifying   TRPML1^Va^: Conducts Na^+^; monovalent cation flux suppressed by divalent cations; inwardly rectifying                               TRPML3^Va^: γ = 49 pS at very negative holding potentials with monovalent cations as charge carrier; conducts Na^+^ \> K^+^ \> Cs^+^ with maintained current in the presence of Na^+^, conducts Ca^2+^ and Mg^2+^, but not Fe^2+^, impermeable to protons; inwardly rectifying Wild type TRPML3: γ = 59 pS at negative holding potentials with monovalent cations as charge carrier; conducts Na^+^ \> K^+^ \> Cs^+^ and Ca^2+^ (P~Ca~/P~K~ ≅ 350), slowly inactivates in the continued presence of Na^+^ within the extracellular (extracytosolic) solution; outwardly rectifying
  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Data in the table are for TRPML proteins mutated (*i.e* TRPML1^Va^, TRPML2^Va^ and TRPML3^Va^) at loci equivalent to TRPML3 A419P to allow plasma membrane expression when expressed in HEK-293 cells and subsequent characterisation by patch-clamp recording [@b253],[@b261],[@b275],[@b304],[@b352]. Data for wild type TRPML3 are also tabulated [@b275],[@b276],[@b304],[@b352]. It should be noted that alternative methodologies, particularly in the case of TRPML1, have resulted in channels with differing biophysical characteristics (reviewed by [@b323]).

  ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Nomenclature                 TRPP2                                                                                                                                                                                                                                                                                                                                                                                                                                                            TRPP3
  HGNC, UniProt                PKD2L1, Q9P0L9                                                                                                                                                                                                                                                                                                                                                                                                                                                   PKD2L2, Q9NZM6
  Activators                   Low constitutive activity, enhanced by membrane depolarization; changes in cell volume affect voltage-dependent gating (increased channel opening probability with cell swelling)                                                                                                                                                                                                                                                                                --
  Channel Blockers (IC~50~)    flufenamate, Gd3+, La3+, phenamil (1.4x10^-7^ M), benzamil (1.1x10^-6^ M), EIPA (1.05x10^-5^ M), amiloride (1.43x10^-4^ M)                                                                                                                                                                                                                                                                                                                                       --
  Functional characteristics   γ = 105--137 pS (outward conductance) 184--399 pS (inward conductance), conducts mono- and di-valent cations with a preference for divalents (P~Ca~/P~Na~ = 4.0--4.3); steady state currents rectify outwardly, whereas instantaneous currents show strong inward rectification; activated and subsequently inactivated by intracellular Ca^2+^ (human, but not mouse); inhibited by extracellular acidification and potentiated by extracellular alkalization   --
  ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------

Comments
========

Data in the table are extracted from [@b247],[@b251] and [@b332]. Broadly similar single channel conductance, mono- and di-valent cation selectivity and sensitivity to blockers are observed for TRPP2 co-expressed with TRPP1 [@b250]. Ca^2+^, Ba^2+^ and Sr^2+^ permeate TRPP3, but reduce inward currents carried by Na^+^. Mg^2+^ is largely impermeant and exerts a voltage dependent inhibition that increases with hyperpolarization.

Voltage-gated calcium channels
==============================

Overview
--------

Calcium (Ca^2+^) channels are voltage-gated ion channels present in the membrane of most excitable cells. The nomenclature for Ca^2+^ channels was proposed by [@b359] and approved by the NC-IUPHAR subcommittee on Ca^2+^ channels [@b358]. Ca^2+^ channels form hetero-oligomeric complexes. The α1 subunit is pore-forming and provides the extracellular binding site(s) for practically all agonists and antagonists. The 10 cloned α-subunits can be grouped into three families: (1) the high-voltage activated dihydropyridine-sensitive (L-type, Ca~V~1.x) channels; (2) the high-voltage activated dihydropyridine-insensitive (Ca~V~2.x) channels and (3) the low-voltage-activated (T-type, Ca~V~3.x) channels. Each α1 subunit has four homologous repeats (I--IV), each repeat having six transmembrane domains and a pore-forming region between transmembrane domains S5 and S6. Gating is thought to be associated with the membrane-spanning S4 segment, which contains highly conserved positive charges. Many of the α1-subunit genes give rise to alternatively spliced products. At least for high-voltage activated channels, it is likely that native channels comprise co-assemblies of α1, β and α2--δ subunits. The γ subunits have not been proven to associate with channels other than α1s. The α2--δ1 and α2--δ2 subunits bind gabapentin and pregabalin.

Subunits
========

  ---------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                 Cav1.1                                                                                          Cav1.2                                                                                          Cav1.3                                                                 Cav1.4                                                               Cav2.1
  HGNC, UniProt                CACNA1S, Q13698                                                                                 *CACNA1C*, Q13936                                                                               *CACNA1D*, Q01668                                                      CACNA1F, O60840                                                      *CACNA1A*, O00555
  Activators (EC~50~)          FPL64176, (-)-(S)-BayK8644, SZ(+)-(S)-202-791                                                   FPL64176, (-)-(S)-BayK8644, SZ(+)-(S)-202-791                                                   (-)-(S)-BayK8644                                                       (-)-(S)-BayK8644                                                     --
  Channel Blockers (IC~50~)    calciseptine, diltiazem, nifedipine, verapamil                                                  calciseptine, diltiazem, nifedipine, verapamil                                                  verapamil (less sensitive to dihydropyridine antagonists)              --                                                                   ω-agatoxin IVB, ω-conotoxin MVIIC, ω-agatoxin IVA (P current component) (∼1x10^-9^ M), ω-agatoxin IVA (Q current component) (∼9x10^-8^ M)
  Functional characteristics   High voltage-activated, slow inactivation                                                       High voltage-activated, slow inactivation (Ca^2+^ dependent)                                    Low-moderate voltage-activated, slow inactivation (Ca^2+^ dependent)   Moderate voltage-activated, slow inactivation (Ca^2+^ independent)   Moderate voltage-activated, moderate inactivation
  Comment                      nifedipine, diltiazem, verapamil and calciseptine are examples of dihydropyridine antagonists   nifedipine, diltiazem, verapamil and calciseptine are examples of dihydropyridine antagonists   verapamil is an example of a dihydropyridine antagonist                Ca~v~1.4 is less sensitive to dihydropyridine antagonists            --
  ---------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------

  ---------------------------- ----------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------- ------------------------------------------------------------------
  Nomenclature                 Cav2.2                                          Cav3.1                                                             Cav3.2                                                              Cav3.3
  HGNC, UniProt                *CACNA1B*, Q00975                               CACNA1G, O43497                                                    *CACNA1H*, O95180                                                   *CACNA1I*, Q9P0X4
  Channel Blockers (IC~50~)    ω-conotoxin GVIA, ω-conotoxin MVIIC             kurtoxin, mibefradil, Ni2+ (low sensitivity to Ni^2+^), SB209712   kurtoxin, mibefradil, Ni2+ (high sensitivity to Ni^2+^), SB209712   kurtoxin, mibefradil, Ni2+ (low sensitivity to Ni^2+^), SB209712
  Functional characteristics   High voltage-activated, moderate inactivation   Low voltage-activated, fast inactivation                           Low voltage-activated, fast inactivation                            Low voltage-activated, moderate inactivation
  ---------------------------- ----------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------- ------------------------------------------------------------------

Comments
========

In many cell types, P and Q current components cannot be adequately separated and many researchers in the field have adopted the terminology 'P/Q-type' current when referring to either component. Ziconotide (a synthetic peptide equivalent to ω-conotoxin MVIIA) has been approved for the treatment of chronic pain [@b360].

Voltage-gated proton channel
============================

Overview
--------

The voltage-gated proton channel (provisionally denoted H~v~1) is a putative 4TM proton-selective channel gated by membrane depolarization and which is sensitive to the transmembrane pH gradient [@b361]--[@b363],[@b372],[@b374]. The structure of H~v~1 is homologous to the voltage sensing domain (VSD) of the superfamily of voltage-gated ion channels (*i.e*. segments S1 to S4) and contains no discernable pore region [@b372],[@b374]. Proton flux through H~v~1 is instead most likely mediated by a water wire completed in a crevice of the protein when the voltage-sensing S4 helix moves in response to a change in transmembrane potential [@b371],[@b377]. H~v~1 expresses largely as a dimer mediated by intracellular C-terminal coiled-coil interactions [@b367] but individual promoters nonetheless support gated H^+^ flux via separate conduction pathways [@b365],[@b366],[@b370],[@b375]. Within dimeric structures, the two protomers do not function independently, but display co-operative interactions during gating resulting in increased voltage sensitivity, but slower activation, of the dimeric, *versus* monomeric, complexes [@b364],[@b376].

Subunits
========

  -------------- --------------- ---------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Channel Blockers (IC~50~)                            Functional characteristics
  Hv1            HVCN1, Q96D96   Zn2+ (∼5x10^-7^ -- 2x10^-6^ M), Cd2+ (∼1x10^-5^ M)   Activated by membrane depolarization mediating macroscopic currents with time-, voltage- and pH-dependence; outwardly rectifying; voltage dependent kinetics with relatively slow current activation sensitive to extracellular pH and temperature, relatively fast deactivation; voltage threshold for current activation determined by pH gradient (ΔpH = pH~o~ -pH~i~) across the membrane
  -------------- --------------- ---------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

The voltage threshold (V~thr~) for activation of Hv1 is not fixed but is set by the pH gradient across the membrane such that V~thr~ is positive to the Nernst potential for H^+^, which ensures that only outwardly directed flux of H^+^ occurs under physiological conditions [@b361]--[@b363]. Phosphorylation of H~v~1 within the N-terminal domain by PKC enhances the gating of the channel [@b368]. Tabulated IC~50~ values for Zn^2^+ and Cd^2+^ are for heterologously expressed human and mouse H~v~1 [@b372],[@b374]. Zn^2+^ is not a conventional pore blocker, but is coordinated by two, or more, external protonation sites involving histamine residues [@b372]. Zn^2+^ binding may occur at the dimer interface between pairs of histamine residues from both monomers where it may interfere with channel opening [@b369]. Mouse knockout studies demonstrate that H~v~1 participates in charge compensation in granulocytes during the respiratory burst of NADPH oxidase-dependent reactive oxygen species production that assists in the clearance of bacterial pathogens [@b373]. Additional physiological functions of H~v~1 are reviewed by [@b361].

Voltage-gated sodium channels
=============================

Overview
--------

Sodium channels are voltage-gated sodium-selective ion channels present in the membrane of most excitable cells. Sodium channels comprise of one pore-forming α subunit, which may be associated with either one or two β subunits [@b380]. α-Subunits consist of four homologous domains (I--IV), each containing six transmembrane segments (S1--S6) and a pore-forming loop. The positively charged fourth transmembrane segment (S4) acts as a voltage sensor and is involved in channel gating. The crystal structure of the bacterial NavAb channel has revealed a number of novel structural features compared to earlier potassium channel structures including a short selectivity filter with ion selectivity determined by interactions with glutamate side chains [@b381]. Interestingly, the pore region is penetrated by fatty acyl chains that extend into the central cavity which may allow the entry of small, hydrophobic pore-blocking drugs [@b381]. Auxiliary β1, β2, β3 and β4 subunits consist of a large extracellular N-terminal domain, a single transmembrane segment and a shorter cytoplasmic domain.

The nomenclature for sodium channels was proposed by Goldin *et al*., (2000) [@b379] and approved by the NC-IUPHAR subcommittee on sodium channels (Catterall *et al*., [@b12], [@b378]).

Subunits
========

  ---------------------------- ------------------------------------------------------------ ----------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------- -------------------------------------------------
  Nomenclature                 Nav1.1                                                       Nav1.2                                                      Nav1.3                                                                    Nav1.4                                                                          Nav1.5                                            Nav1.6                                                       Nav1.7                                                       Nav1.8                                            Nav1.9
  HGNC, UniProt                SCN1A, P35498                                                SCN2A, Q99250                                               SCN3A, Q9NY46                                                             SCN4A, P35499                                                                   SCN5A, Q14524                                     SCN8A, Q9UQD0                                                SCN9A, Q15858                                                SCN10A, Q9Y5Y9                                    SCN11A, Q9UI33
  Activators (EC~50~)          batrachotoxin, veratridine                                   batrachotoxin, veratridine                                  batrachotoxin, veratridine                                                batrachotoxin, veratridine                                                      batrachotoxin, veratridine                        batrachotoxin, veratridine                                   batrachotoxin, veratridine                                   --                                                --
  Channel Blockers (IC~50~)    saxitoxin, tetrodotoxin (Concentration range = 1x10^-8^ M)   saxitoxin,tetrodotoxin (Concentration range = 1x10^-8^ M)   saxitoxin, tetrodotoxin (Concentration range = 2x10^-9^ - 1.5x10^-8^ M)   μ-conotoxin GIIIA, saxitoxin, tetrodotoxin (Concentration range = 5x10^-9^ M)   tetrodotoxin (Concentration range = 2x10^-6^ M)   saxitoxin, tetrodotoxin (Concentration range = 6x10^-9^ M)   saxitoxin, tetrodotoxin (Concentration range = 4x10^-9^ M)   tetrodotoxin (Concentration range = 6x10^-5^ M)   tetrodotoxin (Concentration range = 4x10^-5^ M)
  Functional characteristics   Fast inactivation (0.7 ms)                                   Fast inactivation (0.8 ms)                                  Fast inactivation (0.8 ms)                                                Fast inactivation (0.6 ms)                                                      Fast inactivation (1 ms)                          Fast inactivation (1 ms)                                     Fast inactivation (0.5 ms)                                   Slow inactivation (6 ms)                          Slow inactivation (16 ms)
  ---------------------------- ------------------------------------------------------------ ----------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------- -------------------------------------------------

Comments
========

Sodium channels are also blocked by local anaesthetic agents, antiarrythmic drugs and antiepileptic drugs. There are two clear functional fingerprints for distinguishing different subtypes. These are sensitivity to tetrodotoxin (Na~V~1.5, Na~V~1.8 and Na~V~1.9 are much less sensitive to block) and rate of inactivation (Na~V~1.8 and particularly Na~V~1.9 inactivate more slowly).
